Chimeric protein based on TIGIT and LIGHT

Through chimeric protein technology, the extracellular domains of type I and type II transmembrane proteins are combined to form chimeric proteins that can reverse immunosuppression signals and activate immune responses, solving the problem of difficult to effectively activate anti-cancer immunity in the prior art. Problem, significantly improving the ability to attack tumors.

CN118994414APending Publication Date: 2024-11-22SHATTUCK LABS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410811167.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2017-02-27
Filing Date
2018-02-27
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The prior art is difficult to effectively reverse the immunosuppressive signal and activate the anti-cancer immune response, resulting in poor cancer treatment effect.

Method used

A chimeric protein was developed to form a chimeric protein that can be stable and produce a multimeric state without being bound by theory by combining the extracellular domains of type I and type II transmembrane proteins, using to reverse the immunosuppressive signal and activate the immune response. Specific methods include using extracellular domains of proteins such as TIGIT, LIGHT, etc. to connect to the Fc domain of the antibody to form a chimeric protein capable of binding to the surface receptor of the immune cell, thereby activating or inhibiting specific immune signals.

Benefits of technology

It realizes the activation of anti-tumor immune response in the body, reduces the number of regulated T cells, increases effector T cell activation, reduces immunosuppressed cells, and converts the tumor environment into an inflammatory environment, thereby enhancing the ability to attack tumors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118994414A_ABST
    Figure CN118994414A_ABST
Patent Text Reader

Abstract

The present invention relates, inter alia, to compositions and methods, including TIGIT and / or LIGHT-based chimeric proteins that are useful in the treatment of diseases such as cancer and inflammatory diseases.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of the Chinese patent application with application number 201880013956.1, application date February 27, 2018, and invention name “Chimeric protein based on TIGIT and LIGHT”.

[0002] priority

[0003] This application claims the benefit of and priority to U.S. Provisional Application No. 62 / 464,002, filed on February 27, 2017, the contents of which are hereby incorporated by reference in their entirety.

[0004] Description of the electronically submitted text file

[0005] This application contains a sequence listing. It has been submitted electronically via EFS-Web as an ASCII text file named "SHK-001PC1_SequenceListing_ST25". The sequence listing is 141,613 bytes in size and was created on or about February 27, 2018. The sequence listing is hereby incorporated by reference in its entirety. Technical Field

[0006] In particular, the present invention relates to compositions and methods, including chimeric proteins, that can be used to treat diseases, such as cancer and autoimmune diseases, for immunotherapy. Background Art

[0007] The immune system is central to the body's response to foreign substances that may cause disease. However, many cancers have developed mechanisms to evade the immune system, such as by delivering or propagating immunosuppressive signals. Therefore, there remains a need to develop therapeutic agents that are endowed with multiple functionalities - for example, reversing immunosuppressive signals and stimulating anti-cancer immune responses. Summary of the invention

[0008] Therefore, in various aspects, the present invention provides compositions and methods that can be used for cancer immunotherapy. For example, the present invention is partially related to specific chimeric proteins that reverse or inhibit immunosuppressive signals while providing immune activation or costimulatory signals. Of particular importance, the present invention provides improved chimeric proteins that can maintain a stable and producible multimeric state based on stabilization in the linker region including one or more disulfide bonds without wishing to be bound by theory. Therefore, the compositions and methods of the present invention overcome the various defects of producing bispecific agents.

[0009] In some aspects, the chimeric protein has the following general structure: N-terminus - (a) - (b) - (c) - C-terminus, wherein (a) is a first domain comprising an extracellular domain of a type I transmembrane protein, (b) is a linker comprising at least one cysteine ​​residue capable of forming a disulfide bond (including but not limited to a hinge-CH2-CH3 Fc domain derived from human IgG4), and (c) is a second domain comprising an extracellular domain of a type II transmembrane protein, wherein the linker connects the first domain and the second domain and optionally comprises one or more connecting linkers as described herein.

[0010] For example, in an embodiment, the extracellular domain of the type I transmembrane protein is from TIGIT (VSIG9, VSTM3).

[0011] In an embodiment, the chimeric protein has the following general structure: N-terminus - (a) - (b) - (c) - C-terminus, wherein (a) is a first domain comprising an extracellular domain of a type I transmembrane protein, the transmembrane protein being TIGIT, (b) is a linker comprising at least one cysteine ​​residue capable of forming a disulfide bond (including but not limited to a hinge-CH2-CH3Fc domain derived from human IgG4), and (c) is a second domain comprising an extracellular domain of a type II transmembrane protein selected from 4-1BBL (TNFSF9), GITRL (TNFSF18), TL1A (TNFSF15) and LIGHT (TNFSF14), wherein the linker connects the first domain and the second domain and optionally comprises one or more connecting linkers as described herein.

[0012] For example, in embodiments, the extracellular domain of the type II transmembrane protein is from LIGHT.

[0013] In an embodiment, the chimeric protein has the following general structure: N-terminus - (a) - (b) - (c) - C-terminus, wherein (a) is a first domain comprising an extracellular domain of a type I transmembrane protein selected from PD-1, CD172a (SIRPα) and TIGIT, (b) is a linker comprising at least one cysteine ​​residue capable of forming a disulfide bond (including but not limited to a hinge-CH2-CH3 Fc domain derived from human IgG4), and (c) is a second domain comprising an extracellular domain of a type II transmembrane protein, wherein the linker connects the first domain and the second domain and optionally comprises one or more connecting linkers as described herein.

[0014] In some aspects, a method for treating cancer or inflammatory diseases is provided, which includes administering a pharmaceutical composition of an effective amount of the aforementioned chimeric protein. In embodiments, when combined with the second domain of the chimeric protein, the T cells of the subject are activated, and (a) when combined with the first domain of the chimeric protein, one or more tumor cells are prevented from transmitting immunosuppressive signals, (b) the quantifiable cytokine response in the peripheral blood of the subject is activated, and / or (c) compared with subjects treated with antibodies for type I or type II proteins or their respective ligands or receptors, there is a reduction in tumor growth in subjects in need. In embodiments, the method stimulates the signal transduction of one or more of LIGHT, 4-1BBL, GITRL and TL1A, and activates antigen presenting cells. In embodiments, compared with untreated subjects or subjects treated with antibodies for type I or type II proteins or their respective ligands or receptors, the method reduces the amount or activity of regulatory T cells (Treg). In embodiments, the method increases priming of effector T cells in the draining lymph nodes of a subject compared to an untreated subject or a subject treated with antibodies to type I or type II proteins, or their respective ligands or receptors. In embodiments, the method causes an overall decrease in immunosuppressive cells and a shift toward a more inflammatory tumor environment compared to an untreated subject or a subject treated with antibodies to type I or type II proteins, or their respective ligands or receptors.

[0015] Any aspect or embodiment described herein may be combined with any other aspect or embodiment as disclosed herein. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figures 1A to 1D Type I and II membrane proteins are shown ( Figure 1A and Figure 1C ) can be engineered, where the transmembrane domain and the intracellular domain are removed and joined using a linker sequence ( Figure 1B ) to produce a single chimeric protein, wherein the extracellular domains of the type I membrane protein and the type II membrane protein each face outward in the single chimeric protein. Figure 1B Describe the connection of type I membrane proteins and type II membrane proteins by removing the transmembrane domain and intracellular domain of each protein, and wherein the released extracellular domain (ECD) from each protein has been connected by a linker sequence. The ECD in this description can include the complete amino acid sequence of the candidate type I protein or type II protein that is usually located outside the cell membrane, or any portion thereof that retains binding to an expected receptor or ligand. Figure 1D The linked extracellular domains in a linear construct are depicted, with the extracellular domain of the type I membrane protein facing the "left" side of the construct and the extracellular domain of the type II membrane protein facing the "right" side of the construct.

[0017] Figure 2A , using PD-1-Fc-OX40L chimeric protein as an example, it is shown that tumor cells can express PD-L1 on the cell surface, which can bind to PD-1 ( Figure 2B ). This interaction inhibits the activation of T cells. A chimeric protein comprising the extracellular domain of PD-1 linked to the extracellular domain of OX40L can bind to PD-L1 on the surface of tumor cells, thereby preventing binding to PD-1 on the surface of T cells ( Figure 2C ). The chimeric protein can then be "hung" on the surface of tumor cells, and the OX40L portion of the chimeric protein can then bind to OX40 expressed on the surface of T cells. This will result in the replacement of the inhibitory PD-L1 signal with the co-stimulatory OX40L signal to enhance the anti-tumor activity of T cells. Figure 2D Shown is the synapse formed by the chimeric protein between tumor cells and T cells. FIG. 2A to FIG. 2C The mechanism by which the PD-1-Fc-OX40L chimeric protein binds to its target molecule to create a synapse between cells is shown; thus, PD-1-Fc-OX40L illustrates the mechanism by which the chimeric protein of the present invention operates.

[0018] Figure 3A Shown are Western blots of murine TIGIT-Fc-OX40L chimeric proteins run on SDS-PAGE under reducing conditions, after treatment with N+O deglycosylase, and / or after boiling.

[0019] Figure 3B Western blots of human TIGIT-Fc-OX40L chimeric proteins run on SDS-PAGE under reducing conditions, after treatment with N+O deglycosylase, and / or after boiling are shown. In both cases, specific detection of each domain is indicated by anti-TIGIT, anti-Fc, and anti-OX40L blots.

[0020] Figure 4A Graph showing ELISA of murine TIGIT-Fc-OX40L chimeric protein performed under the following conditions: heavy + light chain capture and detection with Fc-HRP (top left), CD155 / PVR-His capture and detection with IgG (top right), OX40-His capture and detection with antibody to mOX40L (bottom left), and OX40-Fc capture and detection with recombinant CD155 (bottom right). Figure 4BFigure 2 is a graph showing ELISA of human TIGIT-Fc-OX40L chimeric protein performed under the following conditions: heavy + light chain capture and detection with Fc-HRP (top left), CD155 / PVR-His capture and detection with IgG (top right), OX40-His capture and detection with antibody against mOX40L (bottom left), and OX40-Fc capture and detection with recombinant CD155, CD112 or CD113 protein (bottom right).

[0021] Figure 5A The generation of a cell line overexpressing human PVR (CHOK1 / PVR) that can be used to detect binding by constructs containing TIGIT (in Figure 5A , unstained and isoforms are overlapping).

[0022] Figure 5B Shown is the generation of a cell line to overexpress integrin-2 (CHOK1 / integrin2) that can be used to detect binding by TIGIT-containing constructs.

[0023] Figure 5C The generation of a cell line overexpressing integrin-3 (CHOK1 / integrin 3) is shown, which can be used to detect binding by constructs containing TIGIT (in Figure 5C In the figure, unstained, isotype and detection Ab are superimposed).

[0024] Figure 6 Graphs showing binding of mouse TIGIT-Fc-OX40L to CHO-K1 cells expressing mouse PVR (top left), parental CHO-K1 cells lacking PVR (bottom left), or CHO-K1 cells expressing mouse OX40 (right).

[0025] Figure 7 is a table showing the results of identified binding partners for human TIGIT-Fc-OX40L from a microarray containing approximately 6,000 human membrane proteins. In each case, an expected binding partner for each candidate molecule was identified by screening. There was no evidence of nonspecific binding to other human proteins, and binding to Galectin-1 was seen in the screen of all Fc-containing fusion proteins.

[0026] Fig. 8A Shown is a Western blot of murine mCD172a(SIRPα)-Fc-LIGHT chimeric protein run on SDS-PAGE under reducing conditions, after treatment with N+O deglycosylase, and / or after boiling.

[0027] Figure 8BShown is a Western blot of human CD172a (SIRPα)-Fc-LIGHT chimeric protein run on SDS-PAGE under reducing conditions, after treatment with N+O deglycosylase, and / or after boiling.

[0028] Fig. 9A Graph showing ELISA of murine mCD172a(SIRPα)-Fc-LIGHT chimeric protein performed under the following conditions: heavy + light chain capture and detection with Fc-HRP (top left), CD47-His capture and detection with IgG (top right), mLTBR-His capture and detection with antibody against mLIGHT (bottom left), and LTBR His+GST capture and detection with antibody against SIRPα (bottom right). Fig. 9B is a graph showing ELISA of human CD172a (SIRPα)-Fc-LIGHT chimeric protein performed under the following conditions: heavy + light chain capture and detection with Fc-HRP (top left), CD47-His capture and detection with IgG (top right), human LTBR-His capture and detection with antibody against human LIGHT (bottom left), and LTBRHis+GST capture and detection with antibody against SIRPα (bottom right).

[0029] Fig. 10A The graphs show the binding of mouse CD172a (SIRPα)-Fc-LIGHT to CHO-K1 cells expressing mouse CD47 (left side) or CHO-K1 cells expressing mouse LTbR (right side). Fig. 10B is a graph showing the binding of human CD172a(SIRPα)-Fc-LIGHT to CHO-K1 cells expressing mouse CD47 (detection Ab only control peak is on the far left, and the remaining peaks are distributed from left to right in increasing concentration (i.e., 250 is on the far right)).

[0030] Fig.11AIs a graph showing the binding of human CD172a(SIRPα)-Fc-LIGHT and CD172a(SIRPα)-Fc-CD40L to cynomolgus monkey erythrocytes compared to CD47 specific antibodies (clone CC2C6 or CC900002), top left. Lysis of cynomolgus monkey erythrocytes after each treatment is shown in titration curves at bottom left, and exemplary plates are shown on the right. Triton-X was used as a positive control to cause lysis of cynomolgus monkey erythrocytes (for reference, in the top graph, at the X-axis point 2 nM, the curves from top to bottom are anti-CD47 / IgG-APC, anti-CD47-FITC, SIRPα-Fc-LIGHT and SIRPα-Fc-CD40L, and in the bottom graph, at the X-axis point 2, the curves from top to bottom are Triton-X100, anti-CD47 (CC2C6) and anti-CD47 (CC9002), SIRPα-Fc-LIGHT and SIRPα-Fc-CD40L, all overlaid). Fig. 11B is a graph showing the binding of human CD172a(SIRPα)-Fc-LIGHT and CD172a(SIRPα)-Fc-CD40L to human erythrocytes, from each of 3 different human blood donors, compared to CD47 specific antibodies (clone CC2C6 or CC900002). Fig. 11C , lysis of human erythrocytes after each treatment is shown on the left as a titration curve, and an exemplary plate is shown on the right. Triton-X was used as a positive control to cause lysis of cynomolgus monkey erythrocytes. Data for 3 human erythrocyte donors are shown.

[0031] Fig. 12A Shown is a Western blot of murine PD-1-Fc-LIGHT chimeric protein run on SDS-PAGE under reducing conditions, after treatment with N+O deglycosylase, and / or after boiling. Fig. 12B Shown is a Western blot of human PD-1-Fc-LIGHT chimeric protein run on SDS-PAGE under reducing conditions, after treatment with N+O deglycosylase, and / or after boiling.

[0032] Fig.13A is a graph showing ELISA of murine PD-1-Fc-LIGHT chimeric protein performed under the following conditions: heavy + light chain capture and detection with Fc-HRP (left), mLTBR-His capture and detection with antibody against mLIGHT (middle), and mPD-L1 capture and detection with antibody against mLIGHT (right). Fig. 13Bis a graph showing ELISA of human PD-1-Fc-LIGHT chimeric protein performed under the following conditions: heavy + light chain capture and detection with Fc-HRP (left), hLTBR-Fc His capture and detection with hLIGHT for biotinylation (middle), and hPDL1-Fc capture and detection with hLTBR-His / 6x His-HRP (right).

[0033] Fig.14A It is a graph showing the binding of mouse PD-1-Fc-LIGHT to CHO-K1 cells expressing mouse PD-L1 (left) or CHO-K1 cells expressing mouse LTbR (right). Fig. 14B It is a graph showing the binding of human PD-1-Fc-LIGHT to CHO-K1 cells expressing human PD-L1.

[0034] Fig.15A Shown is a Western blot of murine TIGIT-Fc-LIGHT chimeric protein run on SDS-PAGE under reducing conditions, after treatment with N+O deglycosylase, and / or after boiling. Fig. 15B Shown is a Western blot of human TIGIT-Fc-LIGHT chimeric protein run on SDS-PAGE under reducing conditions, after treatment with N+O deglycosylase, and / or after boiling.

[0035] Fig.16A Graph showing ELISA of murine TIGIT-Fc-LIGHT chimeric protein performed under the following conditions: heavy + light chain capture and detection with Fc-HRP (left), CD155 / PVR capture and detection with Fc-HRP (middle), and mLTBR-His capture and detection with antibody against mLIGHT (right). Fig. 16B Graphs showing ELISA of human TIGIT-Fc-LIGHT chimeric protein performed under the following conditions: heavy + light chain capture and detection with Fc-HRP (left), CD155-His capture and detection with IgG (middle), and hCD155-Fc capture and detection with hLTBR-His / 6x His-HRP (right).

[0036] Fig.17 Graphs showing the binding of mouse TIGIT-Fc-LIGHT to CHO-K1 cells expressing mouse PVR (left) or CHO-K1 cells expressing mouse LTbR (right).

[0037] Fig.18Ais a graph showing binding affinity measurements collected by biomembrane interferometry using the Octet system, demonstrating binding of human TIGIT-Fc-LIGHT, CD172a (SIRPα)-Fc-LIGHT, and PD-1-Fc-LIGHT to human LTbR (all graphs from top to bottom: 30, 10, 3.3, 0). Fig.18B are binding affinity measurements collected by biomembrane interferometry using the Octet system, demonstrating binding of human PD-1-Fc-LIGHT to recombinant human PD-L1 and PD-L2 over a range of concentrations (from top to bottom: 500nM ARC x PD-L1, 500nM ARC x PD-L2, 166nM ARC x PD-L1, 166nM ARC xPD-L2, 56nM ARC x PD-L1, 56nM ARC x PD-L2, no ARC).

[0038] Fig.19A is a graph showing binding affinity measurements collected by biomembrane interferometry using an octet system, demonstrating binding of human TIGIT-Fc-OX40L and TIGIT-Fc-LIGHT to recombinant human CD155 / PVR compared to a one-sided TIGIT-Fc fusion protein control (from top to bottom: TIGIT-Fc-LIGHT, TIGIT-Fc-Ox40L, TIGIT-Fc). Fig.19B Binding affinity measurements collected by biointerferometry using the Octet system demonstrate binding of human CD172a(SIRPα)-Fc-LIGHT to recombinant human CD47 compared to a single-sided CD172a(SIRPα)-Fc control or one of two CD47-specific antibody controls (from top to bottom: SIRPa-Fc-LIGHT, anti-CD47, anti-CD47 CC2C6, and SIRP-Fc). Fig.19C Binding affinity measurements collected by biomembrane interferometry using the Octet system demonstrating binding of human PD-1-Fc-LIGHT to recombinant human PD-L1 compared to a single-sided PD-1-Fc control or an anti-PD-L1 control (Atezolizumab) (from top to bottom: PD-1-Fc-LIGHT, anti-PDL1, and PD-1-Fc). Fig.19DBinding affinity measurements collected by biomembrane interferometry using the octet system demonstrate binding of human CD172a (SIRPα)-Fc-LIGHT, TIGIT-Fc-LIGHT or PD-1-Fc-LIGHT to recombinant human LTbR compared to a single-sided LIGHT-Fc fusion protein control or anti-LTbR antibody (from top to bottom: TIGIT-Fc-LIGHT, Sirp1a-Fc-LIGHT, anti-LTbR, PD-1-Fc-LIGHT and LIGHT-Fc).

[0039] Fig. 20A and Fig. 20B Shown is a superantigen cytokine release assay demonstrating the effects of various antibodies mouse TIGIT-Fc-OX40L, mouse CD172a (SIRPα)-Fc-LIGHT, mouse TIGIT-Fc-LIGHT, and mouse PD-1-Fc-LIGHT chimeric proteins on mouse peripheral blood leukocytes activated by Staphylococcal enterotoxin B (SEB). Fig. 20A IL2 secretion is measured, and Fig. 20B TNFα secretion was measured. Fig. 20A and Fig. 20B , the order of conditions for each SEB concentration is reflected from left to right, and the conditions listed in the legend are reflected from top to bottom (e.g., α-PD-1 (RMP1-14) is third from the top in the legend and is therefore third from the left in the figure, PD-1-Fc-LIGHT (10 nM) is third from the bottom in the legend and is therefore third from the right in the figure, etc.). Fig. 20C Compilation of data over multiple superantigen (SEB) concentrations is shown (again, the order of conditions for each SEB concentration is reflected from left to right, and the conditions listed in the legend are reflected from top to bottom).

[0040] FIG. 21A to FIG. 21C Superantigen cytokine release assays are shown, demonstrating that various antibodies human TIGIT-Fc-LIGHT ( Fig.21A )、human TIGIT-Fc-OX40L( Fig. 21B )、human PD-1-Fc-LIGHT and human CD172a(SIRPα)-Fc-LIGHT( Fig. 21C ) Effects of the chimeric protein on human peripheral blood leukocytes activated by Staphylococcal enterotoxin B (SEB).

[0041] FIG. 22A to FIG. 22BResults from in vivo tumor studies are shown, demonstrating the anti-tumor efficacy of mTIGIT-Fc-OX40L, mCD172a (SIRPα)-Fc-LIGHT, mTIGIT-Fc-LIGHT, and mPD-1-Fc-LIGHT chimeric proteins compared to monoclonal antibodies TIGIT, CD47, OX40, PD-1, or a combination of TIGIT and OX40. CT26 tumors were implanted into Balb / c mice and then treated with the indicated regimens. Fig.22A Shown is the evolution of tumor size for each group over 40 days after tumor inoculation. Fig. 22B The overall survival percentage of mice within 40 days after tumor inoculation is shown, and the number of complete tumor rejecters is indicated in the inset table. Fig.22A and Fig. 22B In , treatment conditions are identified by letters.

[0042] Fig.23 Without wishing to be bound by theory, four potential configurations of the PD-1-Fc-OX40L chimeric protein are shown.

[0043] Fig.24 Shown are Western blots of PD-1-Fc-OX40L chimeric proteins run on SDS-PAGE under non-reducing conditions, under reducing conditions, and under reducing conditions and treated with peptide-N-glycosidase F (PNGaseF).

[0044] Fig.25 Shown is a chromatogram of the PD-1-Fc-OX40L chimeric protein run on size exclusion chromatography (SEC).

[0045] Fig.26 Shown are SDS-PAGE gels and native (non-SDS) PAGE gels of PD-1-Fc-OX40L chimeric protein run under non-reducing conditions ("-") or reducing conditions ("+").

[0046] Fig. 27 Shown is a native (non-SDS) PAGE gel of the PD-1-No Fc-OX40L chimeric protein lacking the Fc domain.

[0047] Fig.28 Without wishing to be bound by theory, a model is shown how hexamers and concatemers are formed by the chimeric protein of the invention.

[0048] FIG. 29A to FIG. 29QCharacterization of PD-1-Fc-OX40L chimeric proteins with different connection linker sequences by Western blot analysis is shown. Sequences of different connection linkers are provided in the Examples section below. Specifically, each individual domain of the fusion construct is probed using α-PD-1, α-Fc or α-OX40L antibodies. In each figure, untreated PD-1-Fc-OX40L chimeric protein samples (e.g., controls) in all blots are loaded into lane 1 (without β-mercaptoethanol or PNGase). The samples in lane 2 are treated with the reducing agent β-mercaptoethanol, while the samples in lane 3 are treated with PNGase.

[0049] Fig.30 Shown is the characterization of PD-1-Fc-OX40L chimeric proteins with different linked linker sequences by ELISA-based capture and detection assay targeting the central Fc region of the protein. The protein concentration of each PD-1-Fc-OX40L chimeric protein with different linked linker sequences (#1 to #17) was determined.

[0050] FIG. 31A to FIG. 31P Flow cytometry curves of PD-1-Fc-OX40L chimeric proteins with different linked linker sequences by FACS analysis of PD-L1 or OX40 are shown. The EC values ​​of each PD-1-Fc-OX40L chimeric protein with different linked linker sequences (#2 to #17 - see X-axis labeling and graphs for linker identities in the Examples below) were calculated. 50 value.

[0051] Fig.32 is a table showing connecting linkers and Fc linkers that can be combined into exemplary modular linkers. The exemplary modular linkers shown can be combined with the type I protein and type II protein described herein and / or the extracellular domains of the type I protein and type II protein described herein to form a chimeric protein of the present invention. DETAILED DESCRIPTION

[0052] The present invention is based in part on the discovery that chimeric proteins can be engineered from the extracellular or effector regions of immunomodulatory transmembrane proteins in a manner that exploits the orientation of these proteins (e.g., type I versus type II orientation), thereby allowing the delivery of immunostimulatory and / or immunosuppressive signals, including, for example, masking immunosuppressive signals and replacing immunosuppressive signals with immunostimulatory signals in cancer treatment. Specifically, chimeric proteins based on LIGHT and / or TIGIT have medical uses.

[0053] Chimeric Protein

[0054] In some aspects, the chimeric protein has the following general structure: N-terminus-(a)-(b)-(c)-C-terminus, wherein (a) is a first domain comprising an extracellular domain of a type I transmembrane protein, (b) is a linker having at least one cysteine ​​residue capable of forming a disulfide bond (including but not limited to a hinge-CH2-CH3 Fc domain derived from human IgG4), and (c) is a second domain comprising an extracellular domain of a type II transmembrane protein, wherein the linker connects the first domain and the second domain and optionally comprises one or more connecting linkers as described herein, wherein one of the first extracellular domain and the second extracellular domain is an immunosuppressive signal, and one of the first extracellular domain and the second extracellular domain is an immunostimulatory signal.

[0055] In embodiments, a chimeric protein refers to a recombinant fusion protein, e.g., a single polypeptide having an extracellular domain as described herein. For example, in embodiments, a chimeric protein is translated into a single unit in a cell. In embodiments, a chimeric protein refers to a recombinant protein of multiple polypeptides, e.g., multiple extracellular domains as described herein, which are connected, e.g., in vitro (e.g., with one or more synthetic linkers as described herein) to produce a single unit.

[0056] In embodiments, the chimeric protein is chemically synthesized as one polypeptide, or each domain can be chemically synthesized separately and then combined. In embodiments, a portion of the chimeric protein is translated and a portion is chemically synthesized.

[0057] In embodiments, the extracellular domain refers to a part of a transmembrane protein that can interact with the extracellular environment. In embodiments, the extracellular domain refers to a part of a transmembrane protein that is sufficient to bind to a ligand or receptor and effectively transmit a signal to a cell. In embodiments, the extracellular domain is the entire amino acid sequence of a transmembrane protein outside a cell or cell membrane. In embodiments, the extracellular domain is a part of the amino acid sequence of a transmembrane protein outside a cell or cell membrane, and is required for signal transduction and / or ligand binding, such as methods known in the art can be used to measure (e.g., in vitro ligand binding and / or cell activation assays).

[0058] In the embodiments, an immunosuppressive signal refers to a signal that weakens or eliminates an immune response. For example, in the context of oncology, such a signal can weaken or eliminate anti-tumor immunity. Under normal physiological conditions, inhibitory signals can be used to maintain self-tolerance (e.g., to prevent autoimmune diseases), and can also protect tissues from damage when the immune system responds to pathogenic infections. For example, but not limited to, when such an inhibitory signal is blocked, an immunosuppressive signal can be identified by detecting an increase in cell proliferation, cytokine production, cell killing activity, or phagocytic activity.

[0059] In embodiments, immunostimulatory signals refer to signals that enhance immune responses. For example, in the context of oncology, such signals can enhance anti-tumor immunity. For example, but not limited to, immunostimulatory signals can be identified by directly stimulating the proliferation, cytokine production, killing activity or phagocytic activity of leukocytes. Specific examples include using receptor agonist antibodies or using chimeric proteins encoding ligands of TNF superfamily receptors (respectively OX40L, LIGHT, 4-1BBL, TL1A) to directly stimulate TNF superfamily receptors, such as OX40, LTbR, 4-1BB or TNFRSF25. Stimulation from any of these receptors can directly stimulate the proliferation and cytokine production of individual T cell subsets. Another example includes directly stimulating such immunosuppressive cells by suppressing the activity of immunosuppressive cells. This will include, for example, stimulating CD4+FoxP3+ regulatory T cells with GITR agonist antibodies or chimeric proteins containing GITRL, which will reduce the ability of those regulatory T cells to suppress conventional CD4+ or CD8+ T cell proliferation. In another example, this would include stimulating CD40 on the surface of antigen presenting cells using a CD40 agonist antibody or a chimeric protein containing CD40L, thereby causing activation of antigen presenting cells, including enhancing the ability of these cells to present antigens in the presence of appropriate natural co-stimulatory molecules (including those in the B7 or TNF superfamily). In another example, this would include stimulating LTBR on the surface of lymphocytes or stromal cells using a chimeric protein containing LIGHT, thereby causing activation of lymphocytes and / or production of proinflammatory cytokines or chemokines to further stimulate an immune response, optionally within a tumor.

[0060] Membrane proteins are usually composed of an extracellular domain, one or a series of transmembrane domains and an intracellular domain. Without wishing to be bound by theory, the extracellular domain of a membrane protein is responsible for interacting with a soluble or membrane-bound receptor or ligand. Without wishing to be bound by theory, one or more transmembrane domains are responsible for localizing the protein to the plasma membrane. Without wishing to be bound by theory, the intracellular domain of a membrane protein is responsible for coordinating the interaction with cell signaling molecules to coordinate the intracellular response to the extracellular environment (or vice versa). There are two types of single-pass membrane proteins, i.e., those proteins with an extracellular amino terminal and an intracellular carboxyl terminal (type I) and those proteins with an extracellular carboxyl terminal and an intracellular amino terminal (type II). Both type I and type II membrane proteins can be receptors or ligands. For type I membrane proteins, the amino terminal of the protein faces the extracellular, therefore containing a functional domain responsible for interacting with other binding partners (ligands or receptors) in the extracellular environment. For type II membrane proteins, the carboxyl terminal of the protein faces the extracellular, therefore containing a functional domain responsible for interacting with other binding partners (ligands or receptors) in the extracellular environment. Therefore, the two types of proteins have opposite orientations to each other.

[0061] Because the outward-facing domains of type I and type II membrane proteins are opposite, the extracellular domains of type I and type II membrane proteins can be linked so that the orientation of the 'outward-facing' domains of the molecules is also opposite to each other ( Figure 1D ). Thus, the resulting construct will consist of the extracellular domain of the type I membrane protein on the 'left' side of the molecule connected to the extracellular domain of the type II membrane protein on the 'right' side of the molecule using a linker sequence. This construct can be produced by cloning these three fragments (the extracellular domain of the type I protein, followed by the linker sequence, followed by the extracellular domain of the type II protein) into a vector (plasmid, virus or other), wherein the amino terminus of the complete sequence corresponds to the 'left' side of the molecule containing the type I protein, and the carboxyl terminus of the complete sequence corresponds to the 'right' side of the molecule containing the type II protein. Thus, in embodiments, the chimeric protein of the present invention is engineered in this way.

[0062] In embodiments, the extracellular domain may be used to produce soluble proteins to competitively inhibit signaling of a ligand of the receptor. In embodiments, the extracellular domain may be used to provide artificial signaling.

[0063] In an embodiment, the extracellular domain of a type I transmembrane protein is an immunosuppressive signal.In an embodiment, the extracellular domain of a type II transmembrane protein is an immunostimulatory signal.

[0064] In an embodiment, the chimeric protein of the present invention comprises the extracellular domain of a type I transmembrane protein or a functional fragment thereof. In an embodiment, the chimeric protein of the present invention comprises the extracellular domain of a type II transmembrane protein or a functional fragment thereof. In an embodiment, the chimeric protein of the present invention comprises the extracellular domain of a type I transmembrane protein or a functional fragment thereof, and the extracellular domain of a type II transmembrane protein or a functional fragment thereof.

[0065] In embodiments, the chimeric proteins of the invention can be engineered to target one or more molecules residing on human leukocytes, including, but not limited to, the following extracellular domains (if applicable): SLAMF4, IL-2Rα, 4-1BB / TNFRSF9, IL-2Rβ, ALCAM, BTLA, B7-1, IL-4R, B7-H3, BLAME / SLAMFS, CEACAM1, IL-6R, IL-7Rα, IL-10Rα, IL-10Rβ, IL-12Rβ1, IL-12Rβ2, CD2, IL-13Rα1, IL-13, CD3, CD4, ILT2 / CDS5j, ILT3 / CDS5k, ILT4 / CDS5d, ILT5 / CDS5a, lutegrinα4 / CD49d, CDS, integrin αE / CD103, CD6, integrin αM / CD 11b, CDS, integrin αX / CD11c, integrin β2 / CDIS, KIR / CD15S, CD27 / TNFRSF7, KIR2DL1, CD2S, KIR2DL3, CD30 / TNFRSFS, KIR2DL4 / CD15Sd, CD31 / PECAM-1, KIR2DS4, CD40 ligand / TNFSF5, CD43, LAIR1, CD45, LAIR2, CDS3, leukotriene B4-R1, CDS4 / SLAMF5, NCAM-L1, CD94, NKG2A, CD97, NKG2C, CD229 / SLAMF3, NKG2D, CD2F-10 / SLAMF9, NT-4 , CD69, NTB-A / SLAMF6, common γ chain / IL-2Rγ, osteopontin, CRACC / SLAMF7, PD-1, CRTAM, PSGL-1, CTLA-4, RANK / TNFRSF11A, CX3CR1, CX3CL1, L-selectin, SIRPβ1, SLAM, TCCR / WSX-1, DNAM-1, thymopoietin, EMMPRIN / CD147, TIM-1, EphB6, TIM-2, Fas / TNFRSF6, TIM-3, Fas ligand / TNFSF6, TIM-4, FcγRIII / CD16, TIM-6, TNFR1 / TNFRSF1A, granulysin, TNF RIII / TNFRSF1B, TRAIL RI / TNFRSFIOA, ICAM-1 / CD54, TRAIL R2 / TNFRSF10B, ICAM-2 / CD102, TRAILR3 / TNFRSF10C, IFN-γR1, TRAILR4 / TNFRSF10D, IFN-γR2, TSLP, IL-1R1, LIGHT, LTBR(TNFRSF3) and TSLP R.

[0066] The activation of regulatory T cells is heavily influenced by co-stimulatory and co-inhibitory signals. Two major families of co-stimulatory molecules include the B7 and tumor necrosis factor (TNF) families. These molecules bind to receptors on T cells that belong to the CD28 or TNF receptor families, respectively. Many well-defined co-inhibitors and their receptors belong to the B7 and CD28 families.

[0067] In embodiments, the chimeric proteins of the invention can be engineered to target one or more molecules involved in immunosuppression, including, for example, TIGIT.

[0068] In embodiments, the chimeric proteins of the invention comprise the extracellular domain of an immunosuppressive agent, including, for example, TIGIT.

[0069] In embodiments, the chimeric protein of the invention comprises an extracellular domain of a type I membrane protein having immunosuppressive properties. In embodiments, the chimeric protein is engineered to disrupt, block, reduce and / or inhibit the transmission of immunosuppressive signals.

[0070] In an embodiment, the chimeric protein of the invention comprises an extracellular domain of an immunostimulatory signal which is LIGHT (CD258).

[0071] In an embodiment, the chimeric protein mimics the binding of an inhibitory signal ligand to its cognate receptor (e.g., TIGIT to CD155 / PVR, integrins-2, integrins-3 and / or integrins-4) but inhibits the transmission of the inhibitory signal to an immune cell (e.g., a T cell, macrophage or other leukocyte).

[0072] In an embodiment, the chimeric protein comprises an immunosuppressive receptor extracellular domain and an immunostimulatory ligand extracellular domain, which can, but is not limited to, deliver immunostimulation to T cells while masking the immunosuppressive signal of tumor cells. In an embodiment, the chimeric protein delivers a signal with the end result of T cell activation.

[0073] In embodiments, the chimeric protein comprises an immunosuppressive signal that is an ECD of a receptor for the immunosuppressive signal, and the immunosuppressive signal acts on a tumor cell carrying a cognate ligand of the immunosuppressive signal. In embodiments, the chimeric protein comprises an immunostimulatory signal that is an ECD of a ligand for the immunostimulatory signal, and the immunostimulatory signal acts on a T cell carrying a cognate receptor for the immunostimulatory signal. In embodiments, the chimeric protein comprises both: (i) an immunosuppressive signal that is a receptor for the immunosuppressive signal, and the immunosuppressive signal acts on a tumor cell carrying a cognate ligand for the immunosuppressive signal and (ii) an immunostimulatory signal that is a ligand for the immunostimulatory signal, and the immunostimulatory signal acts on a T cell carrying a cognate receptor for the immunostimulatory signal.

[0074] In embodiments, the chimeric protein of the invention comprises the extracellular domain of one or more immunomodulators described in Mahoney, Nature Reviews Drug Discovery 2015: 14; 561-585, the entire contents of which are hereby incorporated by reference.

[0075] In embodiments, the chimeric protein is capable of binding one or more murine ligands / receptors.

[0076] In embodiments, the chimeric protein is capable of binding one or more human ligands / receptors

[0077] In embodiments, the chimeric protein of the invention comprises an extracellular domain of a type II membrane protein having immunostimulatory properties. In embodiments, the chimeric protein is engineered to enhance, increase and / or stimulate the transmission of an immunostimulatory signal.

[0078] For example, in an embodiment, the extracellular domain of the type I transmembrane protein is from TIGIT.

[0079] TIGIT is a poliovirus receptor (PVR)-like protein, an immunoreceptor containing immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains expressed on T cells. Thus, TIGIT acts as an inhibitory immune checkpoint on both T cells and natural killer (NK) cells, providing an opportunity to target both the adaptive and innate arms of the immune system.

[0080] TIGIT is expressed on NK cells and subsets of activated, memory and regulatory T cells, and specifically on follicular helper T cells within secondary lymphoid organs. CD155 / PVR is upregulated on endothelial cells by IFN-γ and is highly expressed on immature thymocytes, lymph node dendritic cells, and tumor cells of epithelial and neuronal origin. In embodiments, a chimeric protein of the invention (e.g., comprising a TIGIT ECD) regulates any of the cells just described above (e.g., in the context of an immune synapse).

[0081] TIGIT binds CD155 / PVR, bindin-2, bindin-3, and bindin-4. In embodiments, the chimeric protein of the invention (e.g., comprising TIGIT ECD) modulates the binding of TIGIT to CD155 / PVR (e.g., reduces or disrupts binding or signaling). In embodiments, the chimeric protein of the invention (e.g., comprising TIGIT ECD) modulates the binding of TIGIT to bindin-2 (e.g., reduces or disrupts binding or signaling). In embodiments, the chimeric protein of the invention (e.g., comprising TIGIT ECD) modulates the binding of TIGIT to bindin-3 (e.g., reduces or disrupts binding or signaling). In embodiments, the chimeric protein of the invention (e.g., comprising TIGIT ECD) modulates the binding of TIGIT to bindin-4 (e.g., reduces or disrupts binding or signaling).

[0082] In an embodiment, the chimeric protein has the following general structure: N-terminus - (a) - (b) - (c) - C-terminus, wherein (a) is a first domain comprising an extracellular domain of a type I transmembrane protein, the transmembrane protein being TIGIT, (b) is a linker comprising at least one cysteine ​​residue capable of forming a disulfide bond (including but not limited to a hinge-CH2-CH3Fc domain derived from human IgG4), and (c) is a second domain comprising an extracellular domain of a type II transmembrane protein selected from 4-1BBL, GITRL, TL1A and LIGHT, wherein the linker connects the first domain and the second domain and optionally comprises one or more connecting linkers as described herein.

[0083] In an embodiment, the chimeric protein comprises the extracellular domain of the immunosuppressive agent TIGIT and is paired with an immunostimulatory agent as follows: TIGIT / OX-40L; TIGIT / 4-1BBL, TIGIT / LIGHT; TIGIT / GITRL; TIGIT / CD70; TIGIT / CD30L; TIGIT / CD40L; TIGIT / CD137L; TIGIT / TL1A; and TIGIT / OX40L. In an embodiment, the chimeric protein is TIGIT-Fc-4-1BBL, TIGIT-Fc-GITRL, TIGIT-Fc-LIGHT, TIGIT-Fc-OX40L or TIGIT-Fc-TL1A, wherein Fc represents a linker comprising at least a portion of the Fc domain of an antibody and comprising at least one cysteine ​​residue capable of forming a disulfide bond.

[0084] For example, in embodiments, the extracellular domain of the type II transmembrane protein is from LIGHT.

[0085] LIGHT (HVEM-L, TNFSF14 or CD258) is a member of the TNF superfamily, an entity homologous to lymphotoxin, has inducible properties, and is able to compete with herpes simplex virus glycoprotein D for herpes virus entry mediator (HVEM) / tumor necrosis factor (TNF)-related 2. It is a 29-kDa type II transmembrane protein expressed as a homotrimer on activated T cells and DCs, and has three receptors, namely HVEM, LT-β receptor (LTβR, TNFRSF3) and decoy receptor 3 (DcR3). Without wishing to be bound by theory, three receptors with different cellular expression patterns are known to interact with LIGHT: HVEM (TNFRSF14, CD270), detected on activated DC cells, T cells and B cells, NK cells, monocytes and endothelial cells; LTβR, present on follicular DC and stromal cells and binds LIGHT; soluble entity decoy receptor 3 (DcR3), detected on diverse cancer cells such as multiple myeloma and diffuse large B-cell lymphoma. In embodiments, the chimeric protein of the invention can disrupt or reduce the interaction of LIGHT with one or more of these three receptors.

[0086] LIGHT binds to LTBR, ​​and potentially binds to HVEM as well as DcR3. In embodiments, the chimeric protein of the invention (e.g., comprising a LIGHT ECD) regulates the binding of LIGHT to LTBR (e.g., increases or promotes binding or signaling). LTBR is expressed by visceral, lymphoid and other stromal, epithelial and myeloid cells, but not by lymphocytes. In embodiments, the chimeric protein of the invention (e.g., comprising a LIGHT ECD) regulates one or more of visceral, lymphoid and other stromal, epithelial and myeloid cells. In embodiments, the chimeric protein of the invention (e.g., comprising a LIGHT ECD) regulates the binding of LIGHT to HVEM (e.g., increases or promotes binding or signaling). In embodiments, the chimeric protein of the invention (e.g., comprising a LIGHT ECD) regulates the binding of LIGHT to DcR3 (e.g., increases or promotes binding or signaling).

[0087] In an embodiment, the chimeric protein has the following general structure: N-terminus - (a) - (b) - (c) - C-terminus, wherein (a) is a first domain comprising an extracellular domain of a type I transmembrane protein selected from PD-1, CD172a (SIRPα) and TIGIT, (b) is a linker comprising at least one cysteine ​​residue capable of forming a disulfide bond (including but not limited to a hinge-CH2-CH3 Fc domain derived from human IgG4), and (c) is a second domain comprising an extracellular domain of a type II transmembrane protein, wherein the linker connects the first domain and the second domain and optionally comprises one or more connecting linkers as described herein.

[0088] In an embodiment, the chimeric protein comprises the extracellular domain of the immunostimulatory agent LIGHT and is paired with an immunosuppressive agent as follows: PD-1 / LIGHT, CD172a (SIRPα) / LIGHT, and TIGIT / LIGHT. In an embodiment, the chimeric protein is PD-1-Fc-LIGHT, CD172a (SIRPα)-Fc-LIGHT, and TIGIT-Fc-LIGHT, wherein Fc represents a linker comprising at least a portion of the Fc domain of an antibody and comprising at least one cysteine ​​residue capable of forming a disulfide bond.

[0089] In an embodiment, the chimeric protein comprises an extracellular domain of an immunosuppressive agent and is paired with an immunostimulatory agent. In an embodiment, the chimeric protein binds to a cognate receptor or ligand, wherein K D The chimeric protein binds to a cognate receptor or ligand, wherein K D It is about 5nM to about 15nM, for example, about 5nM, about 5.5nM, about 6nM, about 6.5nM, about 7nM, about 7.5nM, about 8nM, about 8.5nM, about 9nM, about 9.5nM, about 10nM, about 10.5nM, about 11nM, about 11.5nM, about 12nM, about 12.5nM, about 13nM, about 13.5nM, about 14nM, about 14.5nM or about 15nM.

[0090] In embodiments, the chimeric protein exhibits enhanced stability and protein half-life. In embodiments, the chimeric protein binds to FcRn with high affinity. In embodiments, the chimeric protein can bind to FcRn, wherein K D For example, the chimeric protein can bind to FcRn, where K DThe chimeric protein may bind to FcRn wherein K is about 1 nM, about 2 nM, about 3 nM, about 4 nM, about 5 nM, about 6 nM, about 7 nM, about 8 nM, about 9 nM, about 10 nM, about 15 nM, about 20 nM, about 25 nM, about 30 nM, about 35 nM, about 40 nM, about 45 nM, about 50 nM, about 55 nM, about 60 nM, about 65 nM, about 70 nM, about 71 nM, about 72 nM, about 73 nM, about 74 nM, about 75 nM, about 76 nM, about 77 nM, about 78 nM, about 79 nM, or about 80 nM. D In embodiments, the chimeric protein does not substantially bind to other Fc receptors with effector function (ie, receptors other than FcRn).

[0091] In an embodiment, a method of treating cancer and / or inflammatory diseases (e.g., any of those described elsewhere herein) by administering to a subject one or more of PD-1-Fc-LIGHT, CD172a (SIRPα)-Fc-LIGHT, and TIGIT-Fc-LIGHT chimeric proteins, wherein the chimeric protein represents at least a portion of the Fc domain of an antibody and comprises at least one cysteine ​​residue capable of forming a disulfide bond. In an embodiment, the method produces a memory response, which, for example, can prevent recurrence. In an embodiment, the method includes a sustained therapeutic effect of one or more of PD-1-Fc-LIGHT, CD172a (SIRPα)-Fc-LIGHT, and TIGIT-Fc-LIGHT, for example, due to the slow dissociation rate (K) of the extracellular domain component. d or K off ) to their respective binding partners to optionally provide a sustained negative signal masking effect and / or a longer positive signal effect, for example, so that effector cells are fully stimulated for an anti-tumor effect.

[0092] In an embodiment, a method of treating cancer or inflammatory diseases (e.g., any of those described elsewhere herein) by administering to a subject one or more of TIGIT-Fc-4-1BBL, TIGIT-Fc-GITRL, TIGIT-Fc-TL1A, and TIGIT-Fc-LIGHT chimeric proteins is provided, wherein the chimeric protein comprises at least a portion of the Fc domain of an antibody and comprises at least one cysteine ​​residue capable of forming a disulfide bond. In an embodiment, the method produces a memory response, which, for example, can prevent relapse. In an embodiment, the method comprises a sustained therapeutic effect of one or more of TIGIT-Fc-4-1BBL, TIGIT-Fc-GITRL, TIGIT-Fc-TL1A, and TIGIT-Fc-LIGHT, for example, due to the slow dissociation rate (K) of the extracellular domain component. d or K off ) to their respective binding partners to optionally provide a sustained negative signal masking effect and / or a longer positive signal effect, for example, so that effector cells are fully stimulated for an anti-tumor effect.

[0093] In embodiments, a chimeric protein of the invention can comprise a variant of an extracellular domain described herein, e.g., having at least about 60%, or at least about 61%, or at least about 62%, or at least about 63%, or at least about 64%, or at least about 65%, or at least about 66%, or at least about 67%, or at least about 68%, or at least about 69%, or at least about 70%, or at least about 71%, or at least about 72%, or at least about 73%, or at least about 74%, or at least about 75%, or at least about 76%, or at least about 77% similarity to the known amino acid or nucleic acid sequence of any of the disclosed extracellular domains. , or at least about 78%, or at least about 79%, or at least about 80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99%) sequence identity, the extracellular domain, such as a human extracellular domain, such as one or more of SEQ ID NO: 2, 4, 7, 10, 13, 16, 19, 22, 25, 27, 29, 31, 37 or 41.

[0094] In an embodiment, a chimeric protein of the invention comprises the extracellular domain of LIGHT (SEQ ID NO: 2).

[0095] In an embodiment, the chimeric protein of the invention comprises the extracellular domain of PD-1 (SEQ ID NO: 4).

[0096] In an embodiment, a chimeric protein of the invention comprises the extracellular domain of TIGIT (SEQ ID NO: 10).

[0097] In an embodiment, the chimeric protein of the invention comprises the extracellular domain of CD172a (SIRPα) (SEQ ID NO: 7).

[0098] In an embodiment, a chimeric protein of the invention comprises the extracellular domain of LIGHT (SEQ ID NO: 2) and the extracellular domain of PD-1 (SEQ ID NO: 4).

[0099] In an embodiment, a chimeric protein of the invention comprises the extracellular domain of LIGHT (SEQ ID NO: 2) and the extracellular domain of TIGIT (SEQ ID NO: 10).

[0100] In an embodiment, a chimeric protein of the invention comprises the extracellular domain of LIGHT (SEQ ID NO: 2) and the extracellular domain of CD172a (SIRPα) (SEQ ID NO: 7).

[0101] In an embodiment, a chimeric protein of the invention comprises a hinge-CH2-CH3 domain from a human IgG4 antibody sequence (SEQ ID NO: 46, 47 or 48).

[0102] In an embodiment, a chimeric protein of the invention comprises a hinge-CH2-CH3 domain from a human IgG4 antibody sequence (SEQ ID NO:46, 47 or 48), and this sequence is flanked by at least one connecting linker selected from the group consisting of: SKYGPPCPSCP (SEQ ID NO:49), SKYGPPCPPCP (SEQ ID NO:50), IEGRMD SEQ ID NO:52 (optionally SKYGPPCPSCP (SEQ ID NO:49) or SKYGPPCPPCP (SEQ ID NO:50) is the N-terminus and one of IEGRMD SEQID NO:52 is the C-terminus).

[0103] In an embodiment, the chimeric protein comprises a modular linker, such as Fig.32 shown.

[0104] In an embodiment, a chimeric protein of the invention comprises the extracellular domain of LIGHT and the extracellular domain of PD-1, using the hinge-CH2-CH3 domain from the human IgG4 antibody sequence as a linker (this PD-1-Fc-LIGHT chimera is SEQ ID NO: 5).

[0105] In an embodiment, a chimeric protein of the invention comprises the extracellular domain of LIGHT and the extracellular domain of TIGIT, using the hinge-CH2-CH3 domain from the human IgG4 antibody sequence as a linker (this TIGIT-Fc-LIGHT chimera is SEQ ID NO: 11).

[0106] In an embodiment, the chimeric protein of the invention comprises the extracellular domain of LIGHT and the extracellular domain of CD172a (SIRPα), using the hinge-CH2-CH3 domain from the human IgG4 antibody sequence as a linker (this CD172a (SIRPα)-Fc-LIGHT chimera is SEQ ID NO: 8).

[0107] In an embodiment, a chimeric protein of the invention comprises the extracellular domain of TIGIT (SEQ ID NO: 10).

[0108] In an embodiment, a chimeric protein of the invention comprises the extracellular domain of 4-1BBL (SEQ ID NO: 13).

[0109] In an embodiment, a chimeric protein of the invention comprises the extracellular domain of GITRL (SEQ ID NO: 16).

[0110] In an embodiment, a chimeric protein of the invention comprises the extracellular domain of TL1A (SEQ ID NO: 19).

[0111] In an embodiment, a chimeric protein of the invention comprises the extracellular domain of LIGHT (SEQ ID NO: 2).

[0112] In an embodiment, a chimeric protein of the invention comprises the extracellular domain of OX40L (SEQ ID NO: 22).

[0113] In an embodiment, a chimeric protein of the invention comprises the extracellular domain of TIGIT (SEQ ID NO: 10) and the extracellular domain of 4-1BBL (SEQ ID NO: 13).

[0114] In an embodiment, a chimeric protein of the invention comprises the extracellular domain of TIGIT (SEQ ID NO: 10) and the extracellular domain of GITRL (SEQ ID NO: 16).

[0115] In an embodiment, a chimeric protein of the invention comprises the extracellular domain of TIGIT (SEQ ID NO: 10) and the extracellular domain of TL1A (SEQ ID NO: 19).

[0116] In an embodiment, a chimeric protein of the invention comprises the extracellular domain of TIGIT (SEQ ID NO: 10) and the extracellular domain of LIGHT (SEQ ID NO: 2).

[0117] In an embodiment, a chimeric protein of the invention comprises the extracellular domain of TIGIT (SEQ ID NO: 10) and the extracellular domain of OX40L (SEQ ID NO: 22).

[0118] In an embodiment, a chimeric protein of the invention comprises a hinge-CH2-CH3 domain from a human IgG4 antibody sequence (SEQ ID NO: 46, 47 or 48).

[0119] In an embodiment, a chimeric protein of the invention comprises a hinge-CH2-CH3 domain from a human IgG4 antibody sequence (SEQ ID NO:46, 47 or 48), and this sequence is flanked by at least one connecting linker selected from the group consisting of: SKYGPPCPSCP (SEQ ID NO:49), SKYGPPCPPCP (SEQ ID NO:50), IEGRMD SEQ ID NO:52 (optionally SKYGPPCPSCP (SEQ ID NO:49) or SKYGPPCPPCP (SEQ ID NO:50) is the N-terminus and one of IEGRMD SEQID NO:52 is the C-terminus).

[0120] In an embodiment, a chimeric protein of the invention comprises the extracellular domain of TIGIT and the extracellular domain of 4-1BBL, using the hinge-CH2-CH3 domain from the human IgG4 antibody sequence as a linker (this TIGIT-Fc-4-1BBL chimera is SEQ ID NO: 14).

[0121] In an embodiment, a chimeric protein of the invention comprises the extracellular domain of TIGIT and the extracellular domain of GITRL, using the hinge-CH2-CH3 domain from the human IgG4 antibody sequence as a linker (this TIGIT-Fc-GITRL chimera is SEQ ID NO: 17).

[0122] In an embodiment, a chimeric protein of the invention comprises the extracellular domain of TIGIT and the extracellular domain of TL1A, using the hinge-CH2-CH3 domain from the human IgG4 antibody sequence as a linker (this TIGIT-Fc-TL1A chimera is SEQ ID NO: 20).

[0123] In an embodiment, a chimeric protein of the invention comprises the extracellular domain of TIGIT and the extracellular domain of LIGHT, using the hinge-CH2-CH3 domain from the human IgG4 antibody sequence as a linker (this TIGIT-Fc-LIGHT chimera is SEQ ID NO: 11).

[0124] In an embodiment, a chimeric protein of the invention comprises the extracellular domain of TIGIT and the extracellular domain of OX40L, using the hinge-CH2-CH3 domain from the human IgG4 antibody sequence as a linker (this TIGIT-Fc-OX40L chimera is SEQ ID NO: 23).

[0125] In an embodiment, a chimeric protein may comprise an extracellular domain from a sequence identified herein in combination with an extracellular domain from another sequence identified herein. For example, the sequence of a TIGIT-Fc-TL1A chimeric protein may comprise an extracellular domain of TIGIT as disclosed above in SEQ ID NO: 10 and an extracellular domain of TL1A as disclosed above in SEQ ID NO: 19.

[0126] In embodiments, additional chimeric proteins and methods of using additional chimeric proteins (e.g., in treating cancer and / or treating inflammatory diseases): TIGIT-Fc-4-1BBL, TIGIT-Fc-CD30L, TIGIT-Fc-FasL, TIGIT-Fc-GITRL, TIGIT-Fc-TL1A, and TIGIT-Fc-TRAIL. The amino acid sequences of 4-1BBL, CD30L, FasL, GITRL, TL1A, and TRAIL include SEQ ID NOs: 12, 26, 30, 15, 18, and 40, respectively. The amino acid sequences of the extracellular domains of 4-1BBL, CD30L, FasL, GITRL, TL1A, and TRAIL are SEQ ID NOs: 13, 27, 31, 16, 19, and 41, respectively.

[0127] In embodiments, a chimeric protein of the invention can be a variant described herein, for example, a chimeric protein of the invention can have an amino acid sequence that is at least about 60%, or at least about 61%, or at least about 62%, or at least about 63%, or at least about 64%, or at least about 65%, or at least about 66%, or at least about 67%, or at least about 68%, or at least about 69%, or at least about 70%, or at least about 71%, or at least about 72%, or at least about 73%, or at least about 74%, or at least about 75%, or at least about 76%, or at least about 77%, or at least about 78%, or at least about 79%, or at least about 80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99%, or at least about 100%, or at least about 101%, or at least about 102%, or at least about 103%, or at least about 104%, or at least about 105%, or at least about 106%, or at least about 107%, or at least about 108%, or at least about 109%. or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99%) sequence identity, the amino acid sequence of the chimeric protein of the invention being, for example, one or more of SEQ ID NO: 5, 8, 11, 14, 17, 20, 23, 42, 43, 44, or 45.

[0128] In an embodiment, the chimeric protein of the present invention comprises an extracellular domain of a human type I transmembrane protein as described in Table 1 of PCT / US2016 / 054598 or a functional fragment thereof. In an embodiment, the chimeric protein of the present invention comprises an extracellular domain of a human type II transmembrane protein as described in Table 2 of PCT / US2016 / 054598 or a functional fragment thereof. In an embodiment, the chimeric protein of the present invention comprises an extracellular domain of a type I transmembrane protein as described in Table 1 of PCT / US2016 / 054598 or a functional fragment thereof, and an extracellular domain of a type II transmembrane protein as described in Table 2 of PCT / US2016 / 054598 or a functional fragment thereof. The entire contents of PCT / US2016 / 054598 are hereby incorporated by reference.

[0129] In an embodiment, a chimeric protein may comprise an amino acid sequence having one or more amino acid mutations relative to any protein sequence described herein. In an embodiment, the one or more amino acid mutations may be independently selected from substitutions, insertions, deletions, and truncations.

[0130] In an embodiment, the amino acid mutation is an amino acid substitution, and may include conservative substitutions and / or non-conservative substitutions.

[0131] For example, "conservative substitutions" can be made based on similarities in polarity, charge, size, solubility, hydrophobicity, hydrophilicity, and / or the amphipathic nature of the amino acid residues involved. The 20 naturally occurring amino acids can be divided into the following six standard amino acid groups: (1) hydrophobic: Met, Ala, Val, Leu, Ile; (2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gln; (3) acidic: Asp, Glu; (4) basic: His, Lys, Arg; (5) residues affecting chain orientation: Gly, Pro; and (6) aromatic: Trp, Tyr, Phe.

[0132] As used herein, "conservative substitution" is defined as the exchange of an amino acid by another amino acid listed in the same group of the six standard amino acid groups shown above. For example, the exchange of Asp by Glu retains a negative charge in the polypeptide so modified. In addition, glycine and proline can be substituted for each other based on their ability to disrupt alpha-helices.

[0133] As used herein, "non-conservative substitution" is defined as the exchange of an amino acid with another amino acid listed in a different group of the six standard amino acid groups (1) to (6) shown above.

[0134] In embodiments, substitutions can also include non-classical amino acids (generally, for example, selenocysteine, pyrrolysine, N-formylmethionine, beta-alanine, GABA and delta-aminolevulinic acid, 4-aminobenzoic acid (PABA), D-isomers of the common amino acids, 2,4-diaminobutyric acid, alpha-aminoisobutyric acid, 4-aminobutyric acid, Abu, 2-aminobutyric acid, gamma-Abu, epsilon-Ahx, 6-aminohexanoic acid, Aib, 2-aminoisobutyric acid, 3-aminopropionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosme, citrulline, homocitrulline, cysteic acid, tert-butylglycine, tert-butylalanine, phenylglycine, cyclohexylalanine, beta-alanine, fluorinated amino acids, designer amino acids (such as beta-methyl amino acids, Cα-methyl amino acids, Nα-methyl amino acids) and amino acid analogs).

[0135] Mutations may also be made to the nucleotide sequence of the chimeric protein by reference to the genetic code including consideration of codon degeneracy.

[0136] In an embodiment, the chimeric protein comprises a linker. In an embodiment, the linker comprises at least one cysteine ​​residue capable of forming a disulfide bond. As described elsewhere herein, without wishing to be bound by theory, such at least one cysteine ​​residue capable of forming a disulfide bond is responsible for maintaining the proper multimeric state of the chimeric protein and allowing efficient production.

[0137] In an embodiment, the linker can be derived from a naturally occurring multidomain protein or is an empirical linker, such as, for example, Chichili et al., (2013), Protein Sci. 22 (2): 153-167, Chen et al., (2013), Adv Drug Deliv Rev. 65 (10): 1357-1369, the entire contents of which are hereby incorporated by reference. In an embodiment, the linker can be designed using a linker design database and computer program, such as Chen et al., (2013), Adv Drug Deliv Rev. 65 (10): 1357-1369 and Crasto et al., (2000), Protein Eng. 13 (5): 309-312, the entire contents of which are hereby incorporated by reference.

[0138] In an embodiment, the linker is a synthetic linker, such as PEG.

[0139] In embodiments, the joint is a polypeptide. In embodiments, the joint length is less than about 500 amino acids, about 450 amino acids, about 400 amino acids, about 350 amino acids, about 300 amino acids, about 250 amino acids, about 200 amino acids, about 150 amino acids or about 100 amino acids. For example, the joint length can be less than about 100, about 95, about 90, about 85, about 80, about 75, about 70, about 65, about 60, about 55, about 50, about 45, about 40, about 35, about 30, about 25, about 20, about 19, about 18, about 17, about 16, about 15, about 14, about 13, about 12, about 11, about 10, about 9, about 8, about 7, about 6, about 5, about 4, about 3 or about 2 amino acids. In embodiments, the joint is flexible. In another embodiment, the joint is rigid.

[0140] In an embodiment, the linker comprises essentially glycine and serine residues (e.g., about 30%, or about 40%, or about 50%, or about 60%, or about 70%, or about 80%, or about 90%, or about 95%, or about 97%, or about 98%, or about 99%, or about 100% glycine and serine).

[0141] In an embodiment, the linker is the hinge region of an antibody (e.g., the hinge region of IgG, IgA, IgD, and IgE, including subclasses (e.g., IgG1, IgG2, IgG3, and IgG4, as well as IgA1 and IgA2)). The hinge region present in IgG, IgA, IgD, and IgE class antibodies acts as a flexible spacer, allowing the Fab portion to move freely in space. In contrast to the constant region, the hinge domain is structurally diverse, varying in both sequence and length in immunoglobulin classes and subclasses. For example, the length and flexibility of the hinge region vary in IgG subclasses. The hinge region of IgG1 comprises amino acids 216-231, and because it is free and flexible, the Fab fragments can rotate around their axis of symmetry and move in a sphere centered on the first of the two inter-heavy chain disulfide bridges. IgG2 has a shorter hinge than IgG1, with 12 amino acid residues and 4 disulfide bridges. The hinge region of IgG2 lacks glycine residues, is relatively short, and contains a rigid polyproline double helix stabilized by an additional inter-heavy chain disulfide bridge. These characteristics limit the flexibility of the IgG2 molecule. The difference between IgG3 and other subclasses is that its unique extended hinge region (about 4 times that of the IgG1 hinge) contains 62 amino acids (including 21 prolines and 11 cysteines) to form a non-flexible polyproline double helix. In IgG3, the Fab fragment is relatively far away from the Fc fragment, so that the molecule has greater flexibility. Compared with other subclasses, the slender hinge in IgG3 is also the reason for its higher molecular weight. The hinge region of IgG4 is shorter than that of IgG1, and its flexibility is between IgG1 and IgG2. It is reported that the flexibility of the hinge region decreases in the order of IgG3>IgG1>IgG4>IgG2. In an embodiment, the linker can be derived from human IgG4 and contain one or more mutations to enhance dimerization (including S228P) or FcRn binding.

[0142] According to crystallographic studies, the immunoglobulin hinge region can be further functionally divided into three regions: the upper hinge region, the core region, and the lower hinge region. See Shin et al., 1992 Immunological Reviews 130:87. The upper hinge region includes the C H1 The amino acid sequence of the upper hinge region is from the carboxyl terminus of the heavy chain to the first residue in the hinge that restricts movement (usually the first cysteine ​​residue that forms an interchain disulfide bond between the two heavy chains). The length of the upper hinge region is related to the segmental flexibility of the antibody. The core hinge region contains the inter-heavy chain disulfide bonds, and the lower hinge region connects the C H2 The amino terminus of the domain and includes the C H2The residues in . Same as above. The core hinge region of wild-type human IgG1 contains the sequence Cys-Pro-Pro-Cys, which, when dimerized by disulfide bond formation, produces a cyclic octapeptide that is considered to act as a pivot, thereby conferring flexibility. In an embodiment, the linker of the present invention comprises one or two or three of the upper hinge region, core region, and lower hinge region of any antibody (e.g., IgG, IgA, IgD, and IgE, including subclasses (e.g., IgG1, IgG2, IgG3, and IgG4, as well as IgA1 and IgA2)). The hinge region may also contain one or more glycosylation sites, including many structurally different types of carbohydrate attachment sites. For example, IgA1 contains five glycosylation sites within a 17-amino acid segment of the hinge region, thereby conferring resistance to intestinal proteases to the hinge region polypeptide, which is considered to be a favorable property of secretory immunoglobulins. In an embodiment, the linker of the present invention comprises one or more glycosylation sites.

[0143] In an embodiment, the linker comprises an Fc domain of an antibody (e.g., a hinge region of IgG, IgA, IgD, and IgE, including subclasses (e.g., IgG1, IgG2, IgG3, and IgG4, as well as IgA1 and IgA2)). In an embodiment, the linker comprises a hinge-CH2-CH3 Fc domain derived from a human IgG4 antibody. In an embodiment, the linker comprises a hinge-CH2-CH3 Fc domain derived from a human IgG1 antibody. In an embodiment, the Fc domain exhibits increased affinity and enhanced binding to a neonatal Fc receptor (FcRn). In an embodiment, the Fc domain comprises one or more mutations that increase affinity and enhance binding to FcRn. Without wishing to be bound by theory, it is believed that increased affinity and enhanced binding to FcRn increase the in vivo half-life of the chimeric protein of the present invention.

[0144] In an embodiment, the Fc domain linker contains one or more amino acid substitutions at amino acid residues 250, 252, 254, 256, 308, 309, 311, 416, 428, 433 or 434 (numbered according to Kabat, as described in Kabat, et al., Sequences of Proteins of Immunological Interest, 5th Edition Public Health Service, National Institutes of Health, Bethesda, Md. (1991), which is expressly incorporated herein by reference) or their equivalents. In one embodiment, the amino acid substitution at amino acid residue 250 is a substitution with glutamine. In one embodiment, the amino acid substitution at amino acid residue 252 is a substitution with tyrosine, phenylalanine, tryptophan or threonine. In one embodiment, the amino acid substitution at amino acid residue 254 is a substitution with threonine. In one embodiment, the amino acid substitution at amino acid residue 256 is a substitution with serine, arginine, glutamine, glutamic acid, aspartic acid or threonine. In one embodiment, the amino acid substitution at amino acid residue 308 is a substitution with threonine. In one embodiment, the amino acid substitution at amino acid residue 309 is a substitution with proline. In one embodiment, the amino acid substitution at amino acid residue 311 is a substitution with serine. In one embodiment, the amino acid substitution at amino acid residue 385 is a substitution with arginine, aspartic acid, serine, threonine, histidine, lysine, alanine or glycine. In one embodiment, the amino acid substitution at amino acid residue 386 is a substitution with threonine, proline, aspartic acid, serine, lysine, arginine, isoleucine or methionine. In one embodiment, the amino acid substitution at amino acid residue 387 is a substitution with arginine, proline, histidine, serine, threonine or alanine. In one embodiment, the amino acid substitution at amino acid residue 389 is a substitution with proline, serine or asparagine. In one embodiment, the amino acid substitution at amino acid residue 416 is a substitution with leucine. In one embodiment, the amino acid substitution at amino acid residue 428 is a substitution with serine. In one embodiment, the amino acid substitution at amino acid residue 433 is a substitution with arginine, serine, isoleucine, proline or glutamine. In one embodiment, the amino acid substitution at amino acid residue 434 is a substitution with histidine, phenylalanine or tyrosine.

[0145] In an embodiment, the Fc domain linker (e.g., comprising an IgG constant region) comprises one or more mutations, such as one or more mutations at amino acid residues 252, 254, 256, 433, 434 or 436 (according to Kabat numbering, as described in Kabat, et al., Sequences of Proteins of Immunological Interest, 5th Edition Public Health Service, National Institutes of Health, Bethesda, Md. (1991), which is expressly incorporated herein by reference). In one embodiment, the IgG constant region comprises a triple M252Y / S254T / T256E mutation or a YTE mutation. In another embodiment, the IgG constant region comprises a triple H433K / N434F / Y436H mutation or a KFH mutation. In yet another embodiment, the IgG constant region comprises a combined YTE and KFH mutation.

[0146] In an embodiment, the modified humanized antibody of the present invention comprises an IgG constant region containing one or more mutations at amino acid residues 250, 253, 307, 310, 380, 416, 428, 433, 434 and 435. Exemplary mutations include T250Q, M428L, T307A, E380A, I253A, H310A, R416S, M428L, H433K, N434A, N434F, N434S and H435A. In one embodiment, the IgG constant region includes an M428L / N434S mutation or an LS mutation. In another embodiment, the IgG constant region includes a T250Q / M428L mutation or a QL mutation. In another embodiment, the IgG constant region includes an N434A mutation. In another embodiment, the IgG constant region includes a T307A / E380A / N434A mutation or an AAA mutation. In another embodiment, the IgG constant region includes I253A / H310A / H435A mutations or IHH mutations. In another embodiment, the IgG constant region includes H433K / N434F mutations. In another embodiment, the IgG constant region includes combined M252Y / S254T / T256E and H433K / N434F mutations.

[0147] Additional exemplary mutations in IgG constant regions are described in, e.g., Robbie, et al., Antimicrobial Agents and Chemotherapy (2013), 57(12):6147-6153, Dall'Acqua et al., JBC (2006), 281(33):23514-24, Dall'Acqua et al., Journal of Immunology (2002), 169:5171-80, Ko et al. Nature (2014) 514:642-645, Grevys et al. Journal of Immunology. (2015), 194(11):5497-508, and U.S. Pat. No. 7,083,784, the entire contents of which are hereby incorporated by reference.

[0148] In an embodiment, the linker comprises the amino acid sequence of SEQ ID NO: 46, or an amino acid sequence having at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto. In an embodiment, SEQ ID NO: 46 is mutated to increase stability and / or half-life. For example, in an embodiment, the linker has the amino acid sequence of SEQ ID NO: 47, or an amino acid sequence having at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto. In an embodiment, the linker comprises the amino acid sequence of SEQ ID NO: 48, or an amino acid sequence having at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto.

[0149] Without wishing to be bound by theory, including a linker comprising at least a portion of the Fc domain in the chimeric protein helps to avoid the formation of insoluble and potentially non-functional protein concatemers and / or aggregates. This is in part due to the presence of cysteines in the Fc domain that are capable of forming disulfide bonds between the chimeric proteins.

[0150] An exemplary Fc stabilizing mutant is S228P. Exemplary Fc half-life extending mutants are T250Q, M428L, V308T, L309P and Q311S, and the linker of the invention may comprise 1, or 2, or 3, or 4, or 5 of these mutants.

[0151] In addition, one or more connecting linkers can be used to connect the Fc domain (e.g., one of SEQ ID NO: 46, SEQ ID NO: 47 or SEQ ID NO: 48, or a domain having at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto) and the extracellular domain in the linker. For example, any one of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, or a variant thereof can connect the extracellular domain as described herein and the linker as described herein. Optionally, any one of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, or a variant thereof is substituted between the extracellular domain as described herein and the linker as described herein. Optionally, any one of SEQ ID NOs: 49 to 95 or a variant thereof is located between the extracellular domain as described herein and the Fc domain as described herein. In an embodiment, the chimeric protein comprises a connecting linker before the Fc domain and a second connecting linker after the Fc domain; thus, the chimeric protein may have the following structure:

[0152] ECD 1–adaptor 1–Fc domain–adaptor 2–ECD 2.

[0153] In embodiments, the first linker and the second linker may be different or they may be the same.

[0154] The amino acid sequences of exemplary linkers are provided in Table 1 below:

[0155] Table 1: Exemplary linkers (Fc domain linkers and connecting linkers)

[0156]

[0157]

[0158] Additional exemplary linkers include, but are not limited to, linkers having the following sequences: LE, GGGGS (SEQ ID NO: 70), (GGGGS) n (n=1-4) (SEQ ID NO:70-73), (Gly)8 (SEQ ID NO:79), (Gly)6 (SEQ IDNO:80), (EAAAK) n (n=1-3)(SEQ ID NO:81-83), A(EAAAK) nA(n=2-5)(SEQ ID NO:84-87), AEAAAKEAAAKA(SEQ ID NO:84), A(EAAAK)4ALEA(EAAAK)4A(SEQ ID NO:88), PAPAP(SEQ ID NO:89), KESGSSVSSEQLAQFRSLD(SEQ ID NO:90), EGKSSGSGSESKST(SEQ ID NO:57), GSAGSAAGSGEF (SEQ ID NO:91) and (XP) n , wherein X represents any amino acid, such as Ala, Lys or Glu.

[0159] In embodiments, the ligation linker comprises essentially glycine and serine residues (e.g., about 30%, or about 40%, or about 50%, or about 60%, or about 70%, or about 80%, or about 90%, or about 95%, or about 97%, or about 98%, or about 99%, or about 100% glycine and serine). For example, in embodiments, the ligation linker is (Gly4Ser) n , wherein n is from about 1 to about 8, e.g., 1, 2, 3, 4, 5, 6, 7, or 8 (SEQ ID NOs: 70 to 77, respectively). In an embodiment, the ligation linker sequence is GGSGGSGGGGSGGGGS (SEQ ID NO: 78). Additional exemplary ligation linkers include, but are not limited to, linkers having the following sequences: LE, (Gly)8 (SEQ ID NO: 79), (Gly)6 (SEQ ID NO: 80), (EAAAK) n (n=1-3)(SEQ ID NO:81-SEQ ID NO:83), A(EAAAK) n A(n=2-5)(SEQ ID NO:84-SEQ ID NO:87), A(EAAAK)4ALEA(EAAAK)4A(SEQ ID NO:88), PAPAP(SEQ ID NO:89), KESGSSVSSEQLAQFRSLD(SEQ ID NO:90), GSAGSAAGSGEF(SEQ ID NO:91) and (XP) n , wherein X represents any amino acid, such as Ala, Lys or Glu. In an embodiment, the linker is GGS.

[0160] In an embodiment, the linker is one or more of the following: GGGSE (SEQ ID NO:92), GSESG (SEQ ID NO:93), GSEGS (SEQ ID NO:94), GEGGSGEGSSGEGSSSEGGGSEGGGSEGGGSEGGS (SEQ ID NO:95), and a linker in which G, S, and E are randomly placed every 4 amino acids.

[0161] In an embodiment, the chimeric protein comprises a modular linker, such as Fig.32 shown.

[0162] In embodiments, the linker may be flexible, including but not limited to highly flexible. In embodiments, the linker may be rigid, including but not limited to a rigid alpha helix.

[0163] In an embodiment, the linker can be functional. For example, but not limited to, the linker can play a role in improving the folding and / or stability of the chimeric protein of the present invention, improving expression, improving pharmacokinetics and / or improving its biological activity. In another example, the linker can play a role in targeting the chimeric protein to a specific cell type or location.

[0164] In embodiments, the chimeric proteins of the invention are capable of promoting immune activation (e.g., against a tumor) and can be used in methods comprising promoting immune activation (e.g., against a tumor). In embodiments, the chimeric proteins of the invention are capable of inhibiting immunosuppression (e.g., allowing tumor survival) and can be used in methods comprising inhibiting immunosuppression (e.g., allowing tumor survival). The chimeric proteins of the invention provide improved immune activation and / or improved inhibition of immunosuppression due to the proximity of signaling provided by the chimeric nature of the construct.

[0165] In embodiments, the chimeric proteins of the invention can or can be used in methods comprising modulating the magnitude of an immune response, e.g., modulating the level of effector output. In embodiments, e.g., when used to treat cancer, the chimeric proteins of the invention alter the extent of immunostimulation to increase the magnitude of a T cell response, including, but not limited to, stimulation of increased levels of cytokine production, proliferation, or targeted killing potential, as compared to immunosuppression.

[0166] In an embodiment, the chimeric protein of the present invention can or can be used in an embodiment to involve masking inhibitory ligands on the surface of tumor cells and replacing the immunosuppressive ligands with immunostimulatory ligands. Therefore, the chimeric protein of the present invention can or can be used in an embodiment to involve reducing or eliminating inhibitory immune signals and / or increasing or activating immunostimulatory signals. For example, tumor cells carrying inhibitory signals (and thus escaping immune responses) can be replaced by positive signals bound to T cells, and then T cells can attack tumor cells. Therefore, in an embodiment, the construct of the present invention masks inhibitory immune signals and activates stimulating immune signals. Such beneficial properties are enhanced by a single construction method of the chimeric protein of the present invention. For example, signal replacement can be achieved almost simultaneously, and signal replacement is customized to be local at clinically important sites (e.g., tumor microenvironment). Additional embodiments apply the same principles to other chimeric protein constructs, such as, for example, (i) the extracellular domain of TIGIT and (ii) the extracellular domain of 4-1BBL; (i) the extracellular domain of TIGIT and (ii) the extracellular domain of GITRL; (i) the extracellular domain of TIGIT and (ii) the extracellular domain of TL1A; (i) the extracellular domain of TIGIT and (ii) the extracellular domain of LIGHT; and (i) the extracellular domain of PD-1 and (ii) the extracellular domain of LIGHT; and (i) the extracellular domain of CD172a (SIRPα) and (ii) the extracellular domain of LIGHT; and (i) the extracellular domain of TIGIT and (ii) the extracellular domain of LIGHT; and the like.

[0167] In an embodiment, the chimeric protein of the invention can or can be used in a method comprising stimulating or enhancing the binding of an immunostimulatory receptor / ligand pair. Exemplary T cell co-stimulatory receptors and their ligands include OX-40:OX40-L, CD27:CD70, CD30:CD30-L, CD40:CD40-L, CD137:CD137-L, HVEM:LIGHT, GITR:GITR-L, TNFRSF25:TL1A, DR5:TRAIL, and BTLA:HVEM. In an embodiment, the chimeric protein of the invention can or can be used in a method comprising inhibiting or reducing the binding of an immunosuppressive receptor / ligand pair. Exemplary T cell co-inhibitory receptors and their ligands include, for example, CTLA-4:CD80 / CD86, PD-1:PD-L1 / PD-L2, BTLA:HVEM, TIM-3:galectin-9 / phosphatidylserine, TIGIT / CD155 or CD112, VISTA / VSIG8, CD172a (SIRPα) / CD47, B7H3R / B7H3, B7H4R / B7H4, CD244 / CD48, TMIGD2 / HHLA2, and the like.

[0168] In embodiments, the chimeric proteins of the invention block, reduce and / or inhibit the binding of PD-1 and PD-L1 or PD-L2 and / or PD-1 to PD-L1 or PD-L2. In embodiments, the chimeric proteins of the invention block, reduce and / or inhibit the activity of CTLA-4 and / or the binding of CTLA-4 to one or more of AP2M1, CD80, CD86, SHP-2 and PPP2R5A. In embodiments, the chimeric proteins of the invention increase and / or stimulate the binding of GITR and / or GITR to one or more of GITR ligands. In embodiments, the chimeric proteins of the invention increase and / or stimulate the binding of OX40 and / or OX40 to one or more of OX40 ligands.

[0169] In an embodiment, the chimeric protein of the present invention can or can be used in a method involving enhancing, restoring, promoting and / or stimulating immunomodulation. In an embodiment, the chimeric protein of the present invention described herein restores, promotes and / or stimulates the activity or activation of one or more immune cells against tumor cells, including but not limited to: T cells, cytotoxic T lymphocytes, T helper cells, natural killer (NK) cells, natural killer T (NKT) cells, anti-tumor macrophages (e.g., M1 macrophages), B cells and dendritic cells. In an embodiment, the chimeric protein of the present invention enhances, restores, promotes and / or stimulates the activity and / or activation of T cells, as a non-limiting example, including activation and / or stimulation of one or more T cell intrinsic signals, including pro-survival signals; autocrine or paracrine growth signals; p38MAPK-, ERK-, STAT-, JAK-, AKT- or PI3K-mediated signals; anti-apoptotic signals; and / or promotes one or more of the following and / or one or more of the following necessary signals: pro-inflammatory cytokine production, or T cell migration, or T cell tumor infiltration.

[0170] In embodiments, the chimeric protein of the present invention can or can be used for methods involving causing one or more T cells (including but not limited to cytotoxic T lymphocytes, T helper cells, natural killer T (NKT) cells), B cells, natural killer (NK) cells, natural killer T (NKT) cells, dendritic cells, monocytes and macrophages (e.g., one or more of M1 and M2) to enter a tumor or tumor microenvironment. In embodiments, the chimeric protein of the present invention can or can be used for methods involving inhibition and / or causing a reduction in the recruitment of immunosuppressive cells (e.g., myeloid suppressor cells (MDSC), regulatory T cells (Treg), tumor-associated neutrophils (TAN), M2 macrophages and tumor-associated macrophages (TAM)) to tumors and / or tumor microenvironments (TME). In embodiments, the therapy of the present invention can change the ratio of M1 macrophages relative to M2 macrophages in the tumor site and / or TME to favor M1 macrophages.

[0171] In an embodiment, the chimeric protein of the present invention can and can be used in a method comprising inhibiting and / or reducing T cell inactivation and / or immune tolerance to a tumor, the method comprising administering an effective amount of the chimeric protein described herein to a subject. In an embodiment, the chimeric protein of the present invention can increase the serum levels of various cytokines, including but not limited to one or more of IFNγ, TNFα, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-13, IL-17A, IL-17F and IL-22. In an embodiment, the chimeric protein of the present invention can enhance IL-2, IL-4, IL-5, IL-10, IL-13, IL-17A, IL-22, TNFα or IFNγ in the serum of the treated subject. In an embodiment, the administration of the chimeric protein of the present invention can enhance TNFα secretion. In a specific embodiment, the administration of the chimeric protein of the present invention can enhance superantigen-mediated TNFα secretion of leukocytes. Detecting this cytokine response can provide a method for determining the optimal dosing regimen for the indicated chimeric protein.

[0172] In an embodiment, the chimeric protein of the present invention inhibits, blocks and / or reduces cell death of anti-tumor CD8+ and / or CD4+ T cells; or stimulates, induces and / or increases cell death of pro-tumor T cells. T cell exhaustion is a state of T cell dysfunction characterized by progressive loss of proliferation and effector function, which ultimately leads to clonal deletion. Therefore, pro-tumor T cells refer to a state of T cell dysfunction that occurs during many chronic infections and cancers. This dysfunction is defined as poor proliferation and / or effector function, persistent expression of inhibitory receptors, and a transcriptional state that is different from that of functional effector T cells or memory T cells. Exhaustion prevents optimal control of infection and tumors. In addition, anti-tumor CD8+ and / or CD4+ T cells refer to T cells that can produce an immune response to tumors. Exemplary pro-tumor T cells include, but are not limited to, Tregs, CD4+ and / or CD8+ T cells expressing one or more checkpoint inhibitory receptors, Th2 cells, and Th17 cells. Checkpoint inhibitory receptors refer to receptors expressed on immune cells that prevent or inhibit uncontrolled immune responses.

[0173] In embodiments, the chimeric proteins of the invention can and may be used in methods comprising increasing the ratio of effector T cells to regulatory T cells. Exemplary effector T cells include ICOS + Effector T cells; cytotoxic T cells (eg, αβTCR, CD3 + 、CD8 + 、CD45RO + ); CD4 + Effector T cells (eg, αβTCR, CD3 + 、CD4 + 、CCR7 + 、CD62Lhi、IL - 7R / CD127 + ); CD8 + Effector T cells (eg, αβTCR, CD3 + 、CD8 + 、CCR7 + 、CD62Lhi、IL - 7R / CD127 + ); effector memory T cells (eg, CD62L low, CD44 + , TCR, CD3 + IL - 7R / CD127 + IL-15R + , CCR7 low); central memory T cells (e.g., CCR7 + 、CD62L + 、CD27 +; or CCR7hi, CD44 + 、CD62Lhi、TCR、CD3 + IL-7R / CD127 + IL-15R + );CD62L + Effector T cells; CD8 + Effector memory T cells (TEM), including early effector memory T cells (CD27 + CD62L - ) and late effector memory T cells (CD27 - CD62L - )(TemE and TemL, respectively); CD127( + )CD25(low / -) effector T cells; CD127( - )CD25( - ) Effector T cells; CD8 + Stem cell memory effector cells (TSCM) (e.g., CD44(low)CD62L(high)CD122(high)sca( + )); TH1 effector T cells (e.g., CXCR3 + CXCR6 + and CCR5 + ; or αβTCR, CD3 + 、CD4 + , IL-12R + IFNγR + CXCR3 + ); TH2 effector T cells (e.g., CCR3 + 、CCR4 + and CCR8 + ; or αβTCR, CD3 + 、CD4 + , IL-4R + IL-33R + 、CCR4 + IL-17RB + , CRTH2 + ); TH9 effector T cells (e.g., αβTCR, CD3 + 、CD4 + ); TH17 effector T cells (e.g., αβTCR, CD3 + 、CD4 + IL-23R + 、CCR6 + , IL-1R + ); CD4 + CD45RO + CCR7+ Effector T cells, CD4 + CD45RO + CCR7( - ) effector T cells; and effector T cells that secrete IL-2, IL-4 and / or IFN-γ. Exemplary regulatory T cells include ICOS + Regulatory T cells, CD4 + CD25 + FOXP3 + Regulatory T cells, CD4 + CD25 + Regulatory T cells, CD4 + CD25 - Regulatory T cells, CD4 + CD25 high regulatory T cells, TIM-3 + PD-1 + Regulatory T cells, lymphocyte activation gene-3 (LAG-3) + Regulatory T cells, CTLA-4 / CD152 + Regulatory T cells, neuropilin-1 (Nrp-1) + Regulatory T cells, CCR4 + CCR8 + Regulatory T cells, CD62L (L-selectin) + Regulatory T cells, CD45RB low regulatory T cells, CD127 low regulatory T cells, LRRC32 / GARP + Regulatory T cells, CD39 + Regulatory T cells, GITR + Regulatory T cells, LAP + Regulatory T cells, 1B11 + Regulatory T cells, BTLA + Regulatory T cells, type 1 regulatory T cells (Tr1 cells), T helper type 3 (Th3) cells, regulatory cells of natural killer T cell phenotype (NKTreg), CD8 + Regulatory T cells, CD8 + CD28 - Regulatory T cells and / or regulatory T cells secreting IL-10, IL-35, TGF-β, TNF-α, galectin-1, IFN-γ and / or MCP1.

[0174] In an embodiment, the chimeric protein generates a memory response that can, for example, prevent relapse, or protect the animal from re-challenge. Thus, an animal treated with the chimeric protein is later able to attack tumor cells and / or prevent tumor development when challenged again after initial treatment with the chimeric protein. Thus, the chimeric protein of the invention stimulates active tumor destruction and also stimulates immune recognition of tumor antigens, which is necessary to design a memory response that can prevent relapse.

[0175] In embodiments, the chimeric proteins of the invention can and may be used in methods comprising transient stimulation of effector T cells for no more than about 12 hours, about 24 hours, about 48 hours, about 72 hours, or about 96 hours, or about 1 week or about 2 weeks. In embodiments, the chimeric proteins of the invention can and may be used in methods comprising transient depletion or inhibition of regulatory T cells for no more than about 12 hours, about 24 hours, about 48 hours, about 72 hours, or about 96 hours, or about 1 week or about 2 weeks. In embodiments, transient stimulation of effector T cells and / or transient depletion or inhibition of regulatory T cells occurs substantially in the patient's blood or in a specific tissue / location (including lymphoid tissue, such as, for example, bone marrow, lymph nodes, spleen, thymus, mucosa-associated lymphoid tissue (MALT), non-lymphoid tissue) or in a tumor microenvironment.

[0176] In embodiments, the chimeric proteins of the present invention provide advantages including, but not limited to, ease of administration and ease of production. This is because two different immunotherapeutic agents are combined into a single product, which allows a single manufacturing process to replace two independent manufacturing processes. In addition, the administration of a single agent instead of two separate agents allows for easier administration and greater patient compliance. In addition, compared to, for example, monoclonal antibodies, which are large multimeric proteins containing many disulfide bonds and post-translational modifications (such as glycosylation), the chimeric proteins of the present invention are easier to manufacture and more cost-effective.

[0177] In embodiments, the chimeric proteins of the invention can be produced in mammalian host cells as a single polypeptide chain that is secretable and fully functional.

[0178] In embodiments, the chimeric protein of the invention unexpectedly provides the extracellular domain component with a slow dissociation rate (K d or K off) with their respective binding partners. In embodiments, this provides unexpectedly long interactions of receptors with ligands (and vice versa). This effect allows for a sustained negative signal masking effect. In addition, in embodiments, this provides for a longer positive signal effect, for example, to allow effector cells to be fully stimulated for anti-tumor effects. For example, the chimeric protein of the invention, for example, by long dissociation rate binding, allows sufficient signaling to provide T cell proliferation and allow anti-tumor attack. As another example, the chimeric protein of the invention, for example, by long dissociation rate binding, allows sufficient signaling to provide release of stimulatory signals (such as, for example, cytokines).

[0179] The stable synapses of cells (e.g., tumor cells with negative signals and T cells that can attack the tumor) promoted by the agents of the invention provide spatial orientation to facilitate tumor reduction - such as positioning T cells to attack tumor cells and / or spatially preventing tumor cells from delivering negative signals, including negative signals beyond those masked by the chimeric proteins of the invention.

[0180] In one embodiment, the serum t 1 / 2 This provides a longer on-target (e.g., within the tumor) half-life (t 1 / 2 ). Such properties may have the combined advantage of reducing off-target toxicity, which may be relevant to the systemic distribution of the chimeric protein.

[0181] In an embodiment, the agents of the invention allow certain immune cells to act, for example, in an anti-tumor manner by preventing and / or destroying NK cells and / or subsets of activated, memory and / or regulatory T cells and / or helper T cells through TIGIT blockade signaling, and optionally generating further immune responses through 4-1BBL- and / or GITRL- and / or TL1A- and / or LIGHT-based stimulatory signaling.

[0182] In embodiments, the agents of the invention allow certain immune cells to act, for example, in an anti-tumor manner by stimulating and / or increasing stimulatory LIGHT-based signaling on, for example, visceral and / or lymphoid and / or other stromal and / or epithelial and / or myeloid cells, and optionally produce a further immune response by blocking or reducing inhibitory signaling based on PD-1 and / or CD172a (SIRPα) and / or TIGIT.

[0183] Furthermore, in embodiments, the chimeric protein of the invention provides a synergistic therapeutic effect as it allows for improved site-specific interaction of the two immunotherapeutic agents.

[0184] In embodiments, the chimeric proteins of the invention provide the potential for reducing ex-site toxicity and / or systemic toxicity.

[0185] In embodiments, the chimeric protein of the present invention provides reduced side effects, such as GI complications, relative to current immunotherapies, such as antibodies to checkpoint molecules as described herein. Exemplary GI complications include abdominal pain, loss of appetite, autoimmune effects, constipation, cramping, dehydration, diarrhea, eating problems, fatigue, flatulence, abdominal effusion or ascites, gastrointestinal (GI) dysbiosis, GI mucositis, inflammatory bowel disease, irritable bowel syndrome (IBS-D and IBS-C), nausea, pain, stool or urine changes, ulcerative colitis, vomiting, retained fluid weight gain and / or weakness.

[0186] Disease; Treatment and Patient Selection

[0187] In embodiments, the invention relates to cancer and / or tumors; for example, the treatment or prevention of cancer and / or tumors. As described elsewhere herein, in embodiments, the treatment of cancer may involve modulating the immune system with the chimeric protein of the invention to favor immunostimulation over immunosuppression.

[0188] Cancer or tumor refers to uncontrolled cell growth and / or abnormally increased cell survival and / or inhibition of apoptosis, which interferes with the normal function of body organs and systems. Includes benign and malignant cancers, polyps, hyperplasia and dormant tumors or micrometastasis. Also includes cells with abnormal proliferation that are not hindered by the immune system (for example, virally infected cells). Cancer can be primary cancer or metastatic cancer. Primary cancer can be a cancer cell region at a clinically detectable origin site, and can be a primary tumor. In contrast, metastatic cancer can be the spread of disease from one organ or part to another non-adjacent organ or part. Metastatic cancer may be caused by cancer cells, and the cancer cells obtain the ability to penetrate and infiltrate the surrounding normal tissues in the local area, thereby forming new tumors, which can be local metastasis. Cancer may also be caused by cancer cells, and the cancer cells obtain the ability to penetrate lymphatic vessels and / or vascular walls, after which cancer cells can circulate to other parts and tissues of the body through the blood (thus becoming circulating tumor cells). Cancer can be due to processes such as lymphatic or blood diffusion. Cancer may also be caused by tumor cells that arrive to lodge in another location, penetrate a blood vessel or wall again, continue to multiply, and eventually form another clinically detectable tumor. Cancer may be this new tumor, which may be a metastatic (or secondary) tumor.

[0189] Cancer can also arise from tumor cells that have metastasized, which can be a secondary or metastatic tumor. The tumor cells can be similar to the cells in the original tumor. For example, if breast cancer or colon cancer metastasizes to the liver, the secondary tumor that is present in the liver is made up of abnormal breast cells or colon cells, not abnormal liver cells. Therefore, the tumor in the liver may be metastatic breast cancer or metastatic colon cancer, not liver cancer.

[0190] Cancer may originate from any tissue. Cancer may originate from melanoma, colon, breast, or prostate, and therefore may be composed of cells that were originally skin, colon, breast, or prostate, respectively. Cancer may also be a blood malignancy, which may be a leukemia or lymphoma. Cancer may invade tissues such as the liver, lungs, bladder, or intestines.

[0191] Representative cancers and / or tumors of the present invention include, but are not limited to, basal cell carcinoma, biliary tract cancer; bladder cancer; bone cancer; brain and central nervous system cancer; breast cancer; peritoneal cancer; cervical cancer; choriocarcinoma; colorectal cancer; connective tissue cancer; cancer of the digestive system; endometrial cancer; esophageal cancer; eye cancer; head and neck cancer; stomach cancer (including gastrointestinal cancer); glioblastoma; liver cancer; hepatocellular carcinoma; intraepithelial neoplasia; kidney cancer; laryngeal cancer; leukemia; liver cancer; lung cancer (e.g., small cell lung cancer, non-small cell lung cancer, lung adenocarcinoma, and lung squamous cell carcinoma); melanoma; myeloma; neuroblastoma; oral cancer (lip, tongue, mouth, and pharynx); ovarian cancer; pancreatic cancer; prostate cancer; retinoblastoma; rhabdomyosarcoma; rectal cancer; respiratory system cancer; salivary gland cancer; sarcoma; skin cancer; squamous cell carcinoma; stomach cancer; testicular cancer; thyroid cancer; uterus or uterus Endometrial cancer; urological cancers; vulvar cancer; lymphomas including Hodgkin and non-Hodgkin lymphomas and B-cell lymphomas (including low-grade / follicular non-Hodgkin lymphoma (NHL), small lymphocytic (SL) NHL; intermediate-grade / follicular NHL; intermediate-grade diffuse NHL; high-grade immunoblastic NHL; high-grade lymphocytic NHL; high-grade small non-lytic cell NHL; bulky NHL; mantle cell lymphoma; AIDS-related lymphoma; and Waldenstrom's macroglobulinemia; chronic lymphocytic leukemia (CLL); acute lymphocytic leukemia (ALL); hairy cell leukemia; chronic myeloblastic leukemia; and other carcinomas and sarcomas; and post-transplant lymphoproliferative disorder (PTLD) and abnormal vascular proliferation associated with keloids, edema (such as that associated with brain tumors), and Meig's syndrome.

[0192] In embodiments, the chimeric protein is used to treat a subject with a treatment-refractory cancer. In embodiments, the chimeric protein is used to treat a subject that is refractory to treatment with one or more immunomodulatory agents. For example, in embodiments, the chimeric protein is used to treat a subject that has not responded to treatment or even progressed after about 12 weeks of treatment. For example, in embodiments, subjects are difficult to treat with PD-1 and / or PD-L1 and / or PD-L2 agents, including, for example, nivolumab (ONO-4538 / BMS-936558, MDX1106, OPDIVO, BRISTOL MYERS SQUIBB), pembrolizumab (KEYTRUDA, MERCK), pidilizumab (CT-011, CURE TECH), MK-3475 (MERCK), BMS 936559 (BRISTOL MYERS SQUIBB), ibrutinib (PHARMACYCLICS / ABBVIE), atezolizumab (TECENTRIQ, GENENTECH) and / or MPDL328OA (ROCHE) refractory patients. For example, in embodiments, subjects are difficult to treat with anti-CTLA-4 agents, such as refractory patients (e.g., melanoma patients) with ipilimumab (YERVOY). Thus, in embodiments, the invention provides methods of treating cancer that rescue patients who have failed to respond to various therapies, including monotherapy with one or more immunomodulatory agents.

[0193] In embodiments, the present invention provides chimeric proteins targeting cells or tissues within a tumor microenvironment. In embodiments, cells or tissues within a tumor microenvironment express one or more targets or binding partners of a chimeric protein. A tumor microenvironment refers to a cellular environment, including cells, secreted proteins, physiological small molecules, and blood vessels in which tumors exist. In embodiments, cells or tissues within a tumor microenvironment are one or more of the following: tumor vasculature; tumor infiltrating lymphocytes; fibroblast reticular cells; endothelial progenitor cells (EPC); cancer-associated fibroblasts; pericytes; other stromal cells; components of the extracellular matrix (ECM); dendritic cells; antigen presenting cells; T cells; regulatory T cells; macrophages; neutrophils; and other immune cells located near a tumor. In embodiments, a chimeric protein of the present invention targets cancer cells. In embodiments, cancer cells express one or more of the targets or binding partners of a chimeric protein.

[0194] In embodiments, the chimeric proteins of the present invention can target cells expressing TIGIT (e.g., cancer cells or immune cells). In embodiments, the chimeric proteins of the present invention can target cells expressing CD155 / PVR (e.g., cancer cells or immune cells). In embodiments, the chimeric proteins of the present invention can target cells expressing integrins-2 (e.g., cancer cells or immune cells). In embodiments, the chimeric proteins of the present invention can target cells expressing integrins-3 (e.g., cancer cells or immune cells). In embodiments, the chimeric proteins of the present invention can target cells expressing integrins-4 (e.g., cancer cells or immune cells).

[0195] In embodiments, the chimeric proteins of the invention can target cells expressing LIGHT (e.g., cancer cells or immune cells). In embodiments, the chimeric proteins of the invention can target cells expressing LTBR (e.g., cancer cells or immune cells). In embodiments, the chimeric proteins of the invention can target cells expressing HVEM (e.g., cancer cells or immune cells). In embodiments, the chimeric proteins of the invention can target cells expressing DcR3 (e.g., cancer cells or immune cells).

[0196] In embodiments, the methods of the invention provide for treatment using the chimeric protein in patients refractory to additional agents, such "additional agents" described elsewhere herein include, but are not limited to, the various chemotherapeutic agents described herein.

[0197] In an embodiment, the chimeric protein is used to treat, control or prevent one or more inflammatory diseases or conditions. Non-limiting examples of inflammatory diseases include acne vulgaris, acute inflammation, allergic rhinitis, asthma, atherosclerosis, atopic dermatitis, autoimmune diseases, autoinflammatory diseases, autosomal recessive spastic ataxia, bronchiectasis, celiac disease, chronic cholecystitis, chronic inflammation, chronic prostatitis, colitis, diverticulitis, familial eosinophilia (fe), glomerulonephritis, glycerol kinase deficiency, suppurative hidradenitis, allergy, inflammation, inflammatory bowel disease, inflammatory pelvic disease, interstitial cystitis, laryngitis, Leigh syndrome, lichen planus, mast cell activation syndrome, mastocytosis, ocular inflammatory diseases, otitis media, pain, pelvic inflammatory disease, reperfusion injury, respiratory diseases, restenosis, rheumatic fever, rheumatoid arthritis, rhinitis, sarcoidosis, septic shock, silicosis and other pneumoconiosis, transplant rejection, tuberculosis and vasculitis.

[0198] In embodiments, the inflammatory disease is an autoimmune disease or condition, such as multiple sclerosis, diabetes, lupus, celiac disease, Crohn's disease, ulcerative colitis, Guillain-Barre syndrome, scleroderma, Goodpasture's syndrome, Wegener's granulomatosis, autoimmune epilepsy, Rasmussen's encephalitis, primary biliary cirrhosis, sclerosing cholangitis, autoimmune hepatitis, Addison's disease, Hashimoto's thyroiditis, fibromyalgia, Meniere's syndrome, transplant rejection (e.g., prevention of allogeneic graft rejection), pernicious anemia, rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis, Sjögren's syndrome, lupus erythematosus, multiple sclerosis, myasthenia gravis, Reiter's syndrome, Grave's disease, and other autoimmune diseases.

[0199] In some aspects, the chimeric agents of the present invention are used to eliminate intracellular pathogens. In some aspects, the chimeric agents of the present invention are used to treat one or more infections. In embodiments, the chimeric proteins of the present invention are used in methods for treating viral infections (including, for example, HIV and HCV), parasitic infections (including, for example, malaria), and bacterial infections. In embodiments, infection induces immunosuppression. For example, HIV infection often causes immunosuppression in infected subjects. Therefore, as described elsewhere herein, in embodiments, the treatment of such infections may involve regulating the immune system with the chimeric proteins of the present invention to favor immunostimulation over immunosuppression. Alternatively, the present invention provides methods for treating infections that induce immune activation. For example, intestinal worm infections are associated with chronic immune activation. In these embodiments, the treatment of such infections may involve regulating the immune system with the chimeric proteins of the present invention to favor immunosuppression over immunostimulation.

[0200] In embodiments, the present invention provides methods for treating viral infections, including but not limited to acute or chronic viral infections, such as respiratory tract infections, papillomavirus infections, herpes simplex virus (HSV) infections, human immunodeficiency virus (HIV) infections, and viral infections of internal organs, such as hepatitis virus infections. In embodiments, viral infections are caused by viruses of Flaviviridae. In embodiments, the viruses of Flaviviridae are selected from yellow fever virus, West Nile virus, dengue virus, Japanese encephalitis virus, St. Louis encephalitis virus, and hepatitis C virus. In embodiments, viral infections are caused by viruses of Picornaviridae (e.g., poliovirus, rhinovirus, coxsackievirus). In embodiments, viral infections are caused by members of Orthomyxoviridae (e.g., influenza virus). In embodiments, viral infections are caused by members of Retroviridae (e.g., slow virus). In embodiments, the viral infection is caused by a member of the Paramyxoviridae family (e.g., respiratory syncytial virus, human parainfluenza virus, mumps virus (e.g., mumps virus), measles virus, and human metapneumovirus). In embodiments, the viral infection is caused by a member of the Bunyaviridae family (e.g., hantavirus). In embodiments, the viral infection is caused by a member of the Reoviridae family (e.g., rotavirus).

[0201] In embodiments, the invention provides methods of treating parasitic infections, such as protozoan or helminth infections. In embodiments, the parasitic infection is caused by a protozoan parasite. In embodiments, the oritiziab parasite is selected from an intestinal protozoan, a tissue protozoan, or a blood protozoan. Exemplary protozoan parasites include, but are not limited to, Entamoeba hystolytica, Giardia lamblia, Cryptosporidium muris, Trypanosomatida gambiense, Trypanosomatidarhodesiense, Trypanosomatida crusi, Leishmania mexicana, Leishmania braziliensis, Leishmania tropicala, Leishmania donovani, Toxoplasma gondii, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, Plasmodium falciparum, Trichomonas vaginalis ... vaginalis and Histomonas meleagridis. In embodiments, parasitic infections are by helminth parasites, such as nematodes (e.g., Adenophorea). In embodiments, the parasite is selected from the class Adenophorea (e.g., Trichuris trichiura, Ascaris lumbricoides, Enterobius vermicularis, Ancylostoma duodenale, Necator americanus, Strongyloides stercoralis, Wuchereria bancrofti, Dracunculus medinensis). In embodiments, the parasite is selected from the class Trematodes (e.g., Schistosoma, Liver Fluke, Intestinal Fluke, and Lung Fluke).In an embodiment, the parasite is selected from the group consisting of Schistosoma mansoni, Schistosoma haematobium, Schistosoma japonicum, Fasciola hepatica, Fasciolagigantica, Heterophyes, Paragonimus westermani. In an embodiment, the parasite is selected from the group consisting of tapeworms (e.g., Taenia solium, Taenia saginata, Hymenolepis nana, Echinococcus granulosus).

[0202] In embodiments, the invention provides methods for treating bacterial infections. In embodiments, bacterial infections are caused by gram-positive bacteria, gram-negative bacteria, aerobic bacteria and / or anaerobic bacteria. In embodiments, bacteria are selected from, but not limited to, Staphylococcus, Lactobacillus, Streptococcus, Sarcina, Escherichia, Enterobacter, Klebsiella, Pseudomonas, Acinetobacter, Mycobacterium, Proteus ), Campylobacter, Citrobacter, Nisseria, Bacillus, Bacteroides, Peptococcus, Clostridium, Salmonella, Shigella, Serratia, Haemophilus, Brucella, and other organisms. In an embodiment, the bacteria is selected from, but not limited to, Pseudomonas aeruginosa, Pseudomonas fluorescens, Pseudomonas acidovorans, Pseudomonas alcaligenes, Pseudomonas putida, Stenotrophomonasmaltophilia, Burkholderia cepacia, Aeromonashydrophilia, Escherichia coli, Citrobacter freundii, Salmonella typhimurium, Salmonella typhi, Salmonella paratyphi, Salmonella enteritidis, enteritidis), Shigella dysenteriae, Shigella flexneriflexneri, Shigella sonnei, Enterobacter cloacae, Enterobacter aerogenes, Klebsiella pneumoniae, Klebsiella oxytoca, Serratia marcescens, Francisella tularensis, Morganella morganii, Proteus mirabilis, Proteus vulgaris, Providencia alcalifaciens, Providencia rettgeri, Providencia stuartii, Acinetobacter baumannii, baumannii), Acinetobacter calcoaceticus, Acinetobacter haemolyticus, Yersinia enterocolitica, Yersinia pestis, Yersinia pseudotuberculosis, Yersinia intermedia, Bordetella pertussis, Bordetella parapertussis, Bordetella bronchiseptica, Haemophilus influenzae, Haemophilus parainfluenzae, Haemophilus haemolyticus, Haemophilus parahaemolyticus, Haemophilus ducreyi, Pasteurella multocida, Pasteurella haemolytica, Branhamella catarrhalis, Helicobacter pyloripylori), Campylobacter fetus, Campylobacter jejuni, Campylobacter coli, Borrelia burgdorferi, Vibrio cholerae, Vibrio parahaemolyticus, Legionella pneumophila, Listeria monocytogenes, Neisseria gonorrhoeae, Neisseria meningitidis, Kingella, Moraxella, Gardnerella vaginalis, Bacteroides fragilis, Bacteroides distasonis, Bacteroides 3452A homologous group, Bacteroides vulgatus, Bacteroides ovale, ovalus), Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides eggerthii, Bacteroides splanchnicus, Clostridium difficile, Mycobacterium tuberculosis, Mycobacterium avium, Mycobacterium intracellulare, Mycobacterium leprae, Corynebacterium diphtheriae, Corynebacterium ulcerans, Streptococcus pneumoniae, Streptococcus agalactiae, Streptococcus pyogenes, Enterococcus faecalis, faecalis), Enterococcusfaecium, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Staphylococcus intermedius, Staphylococcus hyicus subsp. hyicus, Staphylococcus haemolyticus, Staphylococcus hominis, or Staphylococcus saccharolyticus.

[0203] In some aspects, the chimeric agent of the present invention is used to treat one or more autoimmune diseases or disorders. In embodiments, the treatment of an autoimmune disease or disorder may involve regulating the immune system with the chimeric protein of the present invention to favor immunosuppression relative to immunostimulation. Exemplary autoimmune diseases or disorders that can be treated with the chimeric protein of the present invention include those diseases or disorders in which the body's own antigens become targets of immune responses, such as rheumatoid arthritis, systemic lupus erythematosus, diabetes, ankylosing spondylitis, Sjögren's syndrome, inflammatory bowel disease (e.g., ulcerative colitis, Crohn's disease), multiple sclerosis, sarcoidosis, psoriasis, Grave's disease, Hashimoto's thyroiditis, psoriasis, allergic reactions (e.g., allergies, hay fever, asthma, and acute edema cause type I allergic reactions) and vasculitis.

[0204] In still other aspects, the invention relates to methods of treating and preventing T cell-mediated diseases and disorders, such as, but not limited to, those described elsewhere herein, as well as inflammatory diseases or disorders, graft-versus-host disease (GVHD), transplant rejection, and T cell proliferative disorders.

[0205] In some aspects, the chimeric agents of the invention are used in methods of activating T cells, for example, via an extracellular domain having an immunostimulatory signal.

[0206] In some aspects, the chimeric agents of the invention are used in methods of preventing cellular transmission of immunosuppressive signals.

[0207] Combination therapy and conjugation

[0208] In embodiments, the invention provides chimeric proteins and methods further comprising administering to a subject an additional agent. In embodiments, the invention relates to co-administration and / or co-formulation. Any of the compositions described herein may be co-formulated and / or co-administered.

[0209] In embodiments, any chimeric protein described herein acts in a synergistic manner when co-administered with another agent and is administered at a dose lower than that typically employed when such agent is used as a monotherapy. In embodiments, any agent mentioned herein can be used in combination with any chimeric protein described herein.

[0210] In embodiments including but not limited to cancer applications, the present invention relates to chemotherapeutic agents as additional agents. Examples of chemotherapeutic agents include but are not limited to alkylating agents such as thiotepa and CYTOXAN cyclophosphamide; alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa and uredopa; ethyleneimines and methylmelamines including hexamethylmelamine, triethylene melamine, triethylene phosphoramide, triethylenethiophosphoramide and trimethylolmelamine; polyacetyl ( For example, bullatacin and bullatacinone); camptothecins (including the synthetic analogue topotecan); bryostatin; callystatin; CC-1065 (including its synthetic analogues adozelesin, carzelesin and bizelesin); nostoc (e.g., nostoc 1 and nostoc 8); pyralidin; duocarmycin (including the synthetic analogues KW-2189 and CB 1-TM1); eleutherobin; pancratistatin; sarcodictyin; spongistatin; nitrogen mustards such as chlorambucil, naphthyl mustard, chlorphosphamide, estramustine, ifosfamide, mechlorethamine, methoxychloramine, melphalan, nembixin, phenesterine, prednimustine, cyclophosphamide, uramustine; nitrosoureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimustine; antibiotics such as enediyne antibiotics (e.g., calicheamicins, particularly calicheamicin gamma and calicheamicin omega (see, e.g., Agnew, Chem. Intl. Ed. Engl., 33:183-186 (1994)); danemycins, including danemycin A; bisphosphonates such as clodronate; ramycin; and the neocarcin chromophores and related chromoprotein enediyne antibiotic chromophores), aclarubicin, actinomycin, anthramycin, azaserine, bleomycin, actinomycin C, carrubicin, carmomycin, carmomycin, chromomycin, actinomycin D, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, ADRIAMYCIN doxorubicin (including morpholine-doxorubicin, cyanomorpholine-doxorubicin, 2-pyrroline-doxorubicin and deoxydoxorubicin), epirubicin, esorubicin, demethoxydaunorubicin, mexilomycin, mitomycins (such as mitomycin C), mycophenolic acid, nogamycin, olivemycin, peplomycin, porfibrinocin, purine oxazolidinone, triferon-doxorubicin, rhodorubicin, streptomycin, streptozocin, tuberculin, ubenimex, zoloft, doxycycline; antimetabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogs such as dimethoate, methotrexate, pteropterin, trimesat; purine analogs such as fludarabine, 6-mercaptopurine, thiopurine, thioguanine; pyrimidine analogs such as cyclocytidine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine; androgens such as calutosterone, drostanolone propionate, cyclothiostanolol, melastane, testolactone; antiadreners such as aminoglutethimide, mitotane, trilostane; folic acid supplements such as folinic acid (frolinic acid), doxycycline, cyclohexidine, doxycycline ... acid); acetoglucuronide; aldophosphamide glycoside; aminolevulinic acid; eniluracil; amsacrine; bestrabucil; bishanqun; edatraxate; demecil; diaziquone; eflornithine; elliptonium acetate; epothilone; etogluconate; gallium nitrate; hydroxyurea; lentinan; lonidamine; maytansine compounds such as maytansine and ansamitocin; mitoguanidine; mitoxantrone; mopidarol; nitramine; pentostatin; belemet; pirarubicin; losoxantrone; podophyllic acid; 2-ethylhydrazide; procarbazine; PSK polysaccharide complex (JHS Natural Products, Eugene, Oreg.); razoxane; rhizomycin; sizofuran; germanium spiroamine; tenuisporic acid; triazoquinone; 2,2',2"-trichlorotriethylamine; trichothecenes (e.g., T-2 toxin, verracurin A, mycloracin A, and anguidine); urethanes; vindesine; dacarbazine; mannitol mustard; dibromomannitol; dibromodulanol; pipobroman; gacytosine; arabinoside ("Ara-C"); cyclophosphamide; thiotepa; taxanes, such as TAXOL paclitaxel (Bristol-Myers Squibb Oncology, Princeton, NJ), ABRAXANE without hydrogenated castor oil, and albumin-engineered nanoparticle formulations of paclitaxel (American Pharmaceutical Partners, Schaumberg, 111.) and TAXOTERE docetaxel (Rhone-Poulenc Rorer, Antony, France); chlorambucil; GEMZAR gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum analogs such as cisplatin, oxaliplatin, and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitoxantrone; vincristine; NAVELBINE vinorelbine; mitoxantrone hydrochloride; teniposide; edatrexate; daunomycin; aminopterin; xeloda; ibandronate; irinotecan (Camptosar, CPT-11) (including regimens of irinotecan with 5-FU and leucovorin); topoisomerase Inhibitor RFS2000; difluoromethylornithine (DMFO); retinoids, such as retinoic acid; capecitabine; compretin; leucovorin (LV); oxaliplatin, including oxaliplatin treatment regimen (FOLFOX); lapatinib (TYKERB); inhibitors of PKC-α, Raf, H-Ras, EGFR (e.g., erlotinib (Tarceva)) and VEGF-A that reduce cell proliferation, and pharmaceutically acceptable salts, acids or derivatives of any of the above. In addition, the treatment method may also include the use of radiation. In addition, the treatment method may also include the use of photodynamic therapy. .

[0211] In embodiments including but not limited to cancer applications, the additional agent of the invention is one or more immunomodulators selected from agents that block, reduce and / or inhibit the binding of PD-1 and PD-L1 or PD-L2 and / or PD-1 to PD-L1 or PD-L2 (for example, without limitation, one or more of the following: nivolumab (ONO-4538 / BMS-936558, MDX1106, OPDIVO, BRISTOL MYERS SQUIBB), pembrolizumab (KEYTRUDA, Merck), MK-3475 (MERCK), BMS936559 (BRISTOL MYERS SQUIBB), atezolizumab (TECENTRIQ, GENENTECH), MPDL328OA (ROCHE)), agents that increase and / or stimulate the binding of CD137 (4-1BB) and / or CD137 (4-1BB) to one or more 4-1BB ligands (for example, without limitation, urelumab (BMS-663513 and anti-4-1BB antibodies), and agents that block, reduce and / or inhibit the activity of CTLA-4 and / or the binding of CTLA-4 to one or more of AP2M1, CD80, CD86, SHP-2 and PPP2R5A and / or the binding of OX40 to OX40L (for example, without limitation, GBR 830 (GLENMARK), MEDI6469 (MEDIMMUNE)).

[0212] In embodiments including but not limited to infectious disease applications, the invention relates to anti-infective drugs as additional agents. In embodiments, the anti-infective drugs are antiviral agents, including but not limited to abacavir, acyclovir, adefovir, amprenavir, atazanavir, cidofovir, darunavir, delavirdine, didanosine, docosanol, efavirenz, elvitegravir, emtricitabine, enfuvirtide, etravirine, famciclovir and foscarnet. In an embodiment, the anti-infective drug is an antibacterial agent, including, but not limited to, cephalosporin antibiotics (cephalexin, cefuroxime, cefadroxil, cefazolin, cephalothin, cefaclor, cefamandole, cefoxitin, cefprozil, and ceftorox); fluoroquinolone antibiotics (ciprofloxacin, levofloxacin, ofloxacin, gatifloxacin, moxifloxacin, and norfloxacin); tetracycline antibiotics (tetracycline, minocycline, oxytetracycline, and doxycycline); penicillin antibiotics (amoxicillin, ampicillin, penicillin V, dicloxacillin, carbenicillin, vancomycin, and methicillin); monocyclic antibiotics (aztreonam); and carbapenem antibiotics (ertapenem, doripenem, imipenem / cilastatin, and meropenem). In an embodiment, anti-infective drugs include antimalarials (e.g., chloroquine, quinine, mefloquine, primaquine, doxycycline, artemether / lumefantrine, atoquatone / proguanil, and sulfadoxine / pyrimethamine), metronidazole, tinidazole, ivermectin, pyrantel pamoate, and albendazole.

[0213] In embodiments including but not limited to autoimmune disease applications, additional agents are immunosuppressants. In embodiments, immunosuppressants are anti-inflammatory agents, such as steroidal anti-inflammatory agents or nonsteroidal anti-inflammatory agents (NSAIDs). Steroids, particularly adrenocortical steroids and synthetic analogs thereof, are well known in the art. Examples of corticosteroids that can be used in the present invention include but are not limited to hydroxytriamcinolone, α-methyldexamethasone, β-methylbetamethasone, beclomethasone dipropionate, betamethasone benzoate, betamethasone dipropionate, betamethasone valerate, clobetasol valerate, hydroxyprednisolone, desoximetasone, dexamethasone, diflorasone diacetate, diflucortolone valerate, fluandranolone (fluadrenolone), fluclosan, flumethasone pivalate, fluosinolone acetonide (fluosinolone acetonide), fluocinolone acetate, flucortine butylesters, fluocortolone, fluprednidene / fluprednylidene, flurandrenolone, halcinonide, hydrocortisone acetate, hydrocortisone butyrate, methylprednisolone, triamcinolone acetonide, cortisone, cortodoxone, flucetonide, fludrocortisone, difluorosone diacetate diacetate), fluradrenoloneacetonide, medrysone, ansinafil, ansifide, betamethasone and its balanced esters, cloprednisone, clocortelone, clescinolone, dicloran, difluprednate, flucloronide, flunisolide, fluorometholone, fluperone, fluprednisolone, hydrocortisone, methylprednisone, paramethasone, prednisolone, prednisone, beclomethasone dipropionate. (NSAIDS) that can be used in the present invention include but are not limited to salicylic acid, acetylsalicylic acid, methyl salicylate, ethylene glycol salicylate, salicylamide, benzyl-2,5-diacetoxybenzoic acid, ibuprofen, flinic acid, naproxen, ketoprofen, etofenamate, phenylbutazone and indomethacin. In an embodiment, the immunosuppressant can be a cytostatic, such as an alkylating agent, an antimetabolite (e.g., azathioprine, methotrexate), a cytotoxic antibiotic, an antibody (e.g., basiliximab, daclizumab, and muromonab), an anti-immunophilin (e.g., cyclosporine, tacrolimus, sirolimus), an interferon, an opioid, a TNF binding protein, mycophenolate mofetil, and a small biologic (e.g., fingolimod, myriocin).

[0214] In embodiments, the chimeric protein described herein (and / or another agent) includes a modified derivative, i.e., a covalent connection to a composition by any type of molecule, such that the covalent connection does not interfere with the activity of the composition. For example, but not limited to, derivatives include compositions modified by, in particular, glycosylation, lipidation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protection / blocking groups, proteolytic cleavage, connection to cell ligands or other proteins, etc. Any of many chemical modifications can be performed by known techniques, including but not limited to specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc. In addition, the derivative may contain one or more non-classical amino acids. In yet other embodiments, the chimeric protein described herein (and / or another agent) also includes a cytotoxic agent, which, in exemplary embodiments, includes toxins, chemotherapeutic agents, radioisotopes, and agents that cause apoptosis or cell death. Such agents may be conjugated to compositions described herein.

[0215] Thus the chimeric proteins described herein (and / or additional agents) can be post-translationally modified to add effector moieties (such as chemical linkers), detectable moieties (such as, for example, fluorescent dyes, enzymes, substrates, bioluminescent materials, radioactive materials, and chemiluminescent moieties), or functional moieties (such as, for example, streptavidin, avidin, biotin, cytotoxins, cytotoxic agents, and radioactive materials).

[0216] preparation

[0217] The chimeric proteins described herein (and / or additional agents) may have sufficient basic functional groups that can react with inorganic or organic acids to form pharmaceutically acceptable salts, or may react with inorganic or organic bases to form pharmaceutically acceptable salts. Pharmaceutically acceptable acid addition salts are formed from pharmaceutically acceptable acids, as is well known in the art. Such salts include, for example, the pharmaceutically acceptable salts listed in Journal of Pharmaceutical Science, 66, 2-19 (1977) and The Handbook of Pharmaceutical Salts; Properties, Selection, and Use. P. H. Stahl and C. G. Wermuth (eds.), Verlag, Zurich (Switzerland) 2002, which are hereby incorporated by reference in their entirety.

[0218] In certain embodiments, the compositions described herein are in the form of pharmaceutically acceptable salts.

[0219] In addition, any chimeric protein described herein (and / or additional agent) can be administered to a subject as a component of a composition comprising a pharmaceutically acceptable carrier or vehicle. Such compositions may optionally include a suitable amount of a pharmaceutically acceptable excipient to provide a form for appropriate administration. Pharmaceutical excipients can be liquids, such as water and oils, including those of petroleum, animal, plant or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, etc. Pharmaceutical excipients can be, for example, saline, gum arabic, gelatin, starch paste, talc, keratin, silica gel, urea, etc. In addition, adjuvants, stabilizers, thickeners, lubricants and colorants can be used. In one embodiment, when administered to a subject, a pharmaceutically acceptable excipient is sterile. When any agent described herein is administered intravenously, water is an available excipient. Saline solutions and aqueous glucose solutions and glycerol solutions can also be used as liquid excipients, particularly for injectable solutions. Suitable pharmaceutical excipients also include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glyceryl monostearate, talc, sodium chloride, skim milk powder, glycerol, propylene, ethylene glycol, water, ethanol, etc. If desired, any agent described herein may also contain a small amount of a wetting agent or emulsifier or a pH buffering agent.

[0220] In embodiments, the compositions described herein are resuspended in saline buffer (including but not limited to TBS, PBS, etc.).

[0221] In embodiments, chimeric proteins can extend half-life or otherwise improve pharmacodynamic and pharmacokinetic properties by conjugation and / or fusion with another agent. In embodiments, chimeric proteins can be fused or conjugated with one or more of PEG, XTEN (e.g., as rPEG), polysialic acid (POLYXEN), albumin (e.g., human serum albumin or HAS), elastin-like protein (ELP), PAS, HAP, GLK, CTP, transferrin, etc. In embodiments, each individual chimeric protein is fused with one or more agents described in BioDrugs (2015) 29: 215–239, the entire contents of which are hereby incorporated by reference.

[0222] Administration, Dosing and Treatment Regimens

[0223] The present invention includes the chimeric protein (and / or other agent) in various formulations. Any chimeric protein (and / or other agent) described herein can take the following forms: solution, suspension, emulsion, drops, tablets, pills, micropills, capsules, capsules containing liquid, powders, sustained-release formulations, suppositories, emulsions, aerosols, sprays, suspensions or any other form suitable for use. DNA or RNA constructs encoding protein sequences can also be used. In one embodiment, the composition is in the form of a capsule (see, for example, U.S. Patent No. 5,698,155). Other examples of suitable pharmaceutical excipients are described in Remington's Pharmaceutical Sciences 1447-1676 (Alfonso R. Gennaro, 19th edition, 1995), which is incorporated herein by reference.

[0224] If necessary, the preparation comprising the chimeric protein (and / or additional agent) may also include a solubilizing agent. In addition, the agent may be delivered with a suitable vehicle or delivery device known in the art. The combination therapy outlined herein may be delivered together in a single delivery vehicle or delivery device. The composition for administration may optionally include a local anesthetic, such as lidocaine, to relieve pain at the injection site.

[0225] Formulations comprising the chimeric protein of the invention (and / or additional agents) can be conveniently provided in the form of unit doses and can be prepared by any method well known in the pharmaceutical art. Such methods generally include the step of associating the therapeutic agent with a carrier consisting of one or more additional ingredients. Typically, the formulation is prepared by uniformly and closely associating the therapeutic agent with a liquid carrier, a refined solid carrier, or both, and then molding the product into the dosage form of the desired formulation (e.g., wet or dry granulation, powder blending, etc., followed by tableting using conventional methods known in the art) when necessary.

[0226] In one embodiment, any chimeric protein described herein (and / or additional agent) is formulated in accordance with routine procedures as a composition suitable for the modes of administration described herein.

[0227] Administration routes include, for example, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, oral, sublingual, intranasal, intracerebral, intravaginal, transdermal, rectal, by inhalation, or topically, particularly to the ear, nose, eye, or skin. In embodiments, the administration is achieved orally or by parenteral injection. In most cases, administration results in the release of any agent described herein into the blood.

[0228] Any chimeric protein (and / or additional agent) described herein can be administered orally. Such chimeric proteins (and / or additional agents) can also be administered by any other conventional route, such as by intravenous infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.), and can be administered together with another biologically active agent. Administration can be systemic or local. Different delivery systems are known, such as encapsulation in liposomes, microparticles, microcapsules, capsules, etc., and can be used for administration.

[0229] In a specific embodiment, it may be desirable to administer locally to an area in need of treatment. In one embodiment, for example, in the treatment of cancer, the chimeric protein (and / or another agent) is administered and / or targeted to a tumor microenvironment or lymph node in a tumor microenvironment (e.g., cells, molecules, extracellular matrix, and / or blood vessels surrounding tumor cells and / or providing nutrition to tumor cells, including, for example, tumor vasculature; tumor infiltrating lymphocytes; fibroblast reticular cells; endothelial progenitor cells (EPC); cancer-associated fibroblasts; pericytes; other stromal cells; components of the extracellular matrix (ECM); dendritic cells; antigen presenting cells; T cells; regulatory T cells; macrophages; neutrophils; and other immune cells located near the tumor) or lymph nodes. In an embodiment, for example, in the treatment of cancer, the chimeric protein (and / or another agent) is administered intratumorally.

[0230] In various embodiments, the chimeric proteins of the invention allow for a dual effect that provides fewer side effects than those seen in conventional immunotherapies (e.g., treatment with one or more of OPDIVO, KEYTRUDA, YERVOY, and TECENTRIQ). For example, the chimeric proteins of the invention reduce or prevent commonly observed immune-related adverse events affecting various tissues and organs, including the skin, gastrointestinal tract, kidneys, peripheral and central nervous systems, liver, lymph nodes, eyes, pancreas, and endocrine system; such as hypophysitis, colitis, hepatitis, pneumonitis, rash, and rheumatic diseases. In addition, local administration of the invention, such as intratumoral administration, avoids adverse events seen in standard systemic administration (e.g., intravenous infusion) when used with conventional immunotherapies (e.g., treatment with one or more of OPDIVO, KEYTRUDA, YERVOY, and TECENTRIQ).

[0231] Dosage forms suitable for parenteral administration (e.g., intravenous, intramuscular, intraperitoneal, subcutaneous and intraarticular injection and infusion) include, for example, solutions, suspensions, dispersions, emulsions, etc. They can also be manufactured in the form of sterile solid compositions (e.g., lyophilized compositions) that can be dissolved or suspended in a sterile injectable medium just before use. They can contain, for example, suspending agents or dispersants known in the art.

[0232] The dosage and dosing regimen of any chimeric protein (and / or additional agent) described herein can depend on various parameters, including but not limited to the disease being treated, the general health of the subject, and the judgment of the administering physician. Any chimeric protein described herein can be administered prior to (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 ​​hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks before), concurrently with, or after (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 ​​hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks after) the administration of the additional agent to a subject in need thereof. In embodiments, administration of any of the chimeric proteins described herein and the additional agent is 1 minute apart, 10 minutes apart, 30 minutes apart, less than 1 hour apart, 1 hour apart, 1 to 2 hours apart, 2 to 3 hours apart, 3 to 4 hours apart, 4 to 5 hours apart, 5 to 6 hours apart, 6 to 7 hours apart, 7 to 8 hours apart, 8 to 9 hours apart, 9 to 10 hours apart, 10 to 11 hours apart, 11 to 12 hours apart, 1 day apart, 2 days apart, 3 days apart, 4 days apart, 5 days apart, 6 days apart, 1 week apart, 2 weeks apart, 3 weeks apart, or 4 weeks apart.

[0233] In embodiments, the present invention relates to the co-administration of a chimeric protein that induces an innate immune response and another chimeric protein that induces an adaptive immune response. In such embodiments, the chimeric protein that induces an innate immune response can be administered before, simultaneously, or after the chimeric protein that induces an adaptive immune response is administered. For example, the administration of the chimeric protein can be 1 minute apart, 10 minutes apart, 30 minutes apart, less than 1 hour apart, 1 hour apart, 1 hour apart to 2 hours apart, 2 hours apart to 3 hours apart, 3 hours apart to 4 hours apart, 4 hours apart to 5 hours apart, 5 hours apart to 6 hours apart, 6 hours apart to 7 hours apart, 7 hours apart to 8 hours apart, 8 hours apart to 9 hours apart, 9 hours apart to 10 hours apart, 10 hours apart to 11 hours apart, 11 hours apart to 12 hours apart, 1 day apart, 2 days apart, 3 days apart, 4 days apart, 5 days apart, 6 days apart, 1 week apart, 2 weeks apart, 3 weeks apart, or 4 weeks apart. In exemplary embodiments, the chimeric protein that induces an innate immune response and the chimeric protein that induces an adaptive response are administered one week apart, or are administered every other week (i.e., the chimeric protein that induces an innate immune response is administered one week before the chimeric protein that induces an adaptive immune response, etc.).

[0234] The dosage of any chimeric protein (and / or additional agent) described herein can depend on several factors, including the severity of the condition, whether the condition is treated or prevented, and the age, weight, and health of the subject to be treated. In addition, information about the pharmacogenomics (the effect of genotype on the pharmacokinetics, pharmacodynamics, or efficacy curves of the therapeutic agent) of a specific subject can affect the dosage used. In addition, the precise individual dosage can be slightly adjusted according to a variety of factors, including the specific combination of agents being administered, the time of administration, the route of administration, the nature of the formulation, the rate of excretion, the specific disease being treated, the severity of the condition, and the anatomical location of the condition. Some dosage variations can be expected.

[0235] For administration of any chimeric protein described herein (and / or additional agent) by parenteral injection, the dosage can be from about 0.1 mg to about 250 mg per day, from about 1 mg to about 20 mg per day, or from about 3 mg to about 5 mg per day. Generally, when administered orally or parenterally, the dosage of any agent described herein can be from about 0.1 mg to about 1500 mg per day, or from about 0.5 mg to about 10 mg per day, or from about 0.5 mg to about 5 mg per day, or from about 200 to about 1,200 mg per day (e.g., about 200 mg, about 300 mg, about 400 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg, about 1,000 mg, about 1,100 mg, about 1,200 mg per day).

[0236] In embodiments, administration of the chimeric protein described herein (and / or additional agent) is by parenteral injection at a dose of about 0.1 mg to about 1500 mg per treatment, or about 0.5 mg to about 10 mg per treatment, or about 0.5 mg to about 5 mg per treatment, or about 200 to about 1,200 mg per treatment (e.g., about 200 mg, about 300 mg, about 400 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg, about 1,000 mg, about 1,100 mg, about 1,200 mg per treatment).

[0237] In embodiments, a suitable dosage of the chimeric protein (and / or additional agent) is in the range of about 0.01 mg / kg to about 100 mg / kg body weight, or about 0.01 mg / kg to about 10 mg / kg body weight of a subject, e.g., about 0.01 mg / kg, about 0.02 mg / kg, about 0.03 mg / kg, about 0.04 mg / kg, about 0.05 mg / kg, about 0.06 mg / kg, about 0.07 mg / kg, about 0.08 mg / kg, about 0.09 mg / kg, about 0.1 mg / kg, about 0.2 mg / kg, about 0.3 mg / kg, about 0.4 mg / kg, about 0.5 mg / kg kg, about 0.6 mg / kg, about 0.7 mg / kg, about 0.8 mg / kg, about 0.9 mg / kg, about 1 mg / kg, about 1.1 mg / kg, about 1.2 mg / kg, about 1.3 mg / kg, about 1.4 mg / kg, about 1.5 mg / kg, about 1.6 mg / kg, about 1.7 mg / kg, about 1.8 mg / kg, 1.9 mg / kg, about 2 mg / kg, about 3 mg / kg, about 4 mg / kg, about 5 mg / kg, about 6 mg / kg, about 7 mg / kg, about 8 mg / kg, about 9 mg / kg, about 10 mg / kg body weight, including all values ​​and ranges therebetween.

[0238] In another embodiment, delivery can be in a vesicle, specifically in a liposome (see, Langer, 1990, Science 249: 1527-1533; Treat et al., in Liposomes in therapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353-365 (1989).

[0239] Any chimeric protein described herein (and / or additional agent) can be administered by controlled or sustained release or by delivery devices well known to those of ordinary skill in the art. Examples include, but are not limited to, those described in U.S. Pat. Nos. 3,845,770; 3,916,899; 3,536,809; 3,598,123; 4,008,719; 5,674,533; 5,059,595; 5,591,767; 5,120,548; 5,073,543; 5,639,476; 5,354,556; and 5,733,556; each of which is incorporated herein by reference. Such dosage forms can be adapted to provide controlled or sustained release of one or more active ingredients using, for example, hydroxypropylmethylcellulose, other polymer matrices, gels, permeable membranes, osmotic systems, multilayer coatings, microparticles, liposomes, microspheres, or combinations thereof, to provide desired release profiles in varying proportions. The controlled or sustained release of active ingredients can be stimulated by various conditions, including, but not limited to, changes in pH, changes in temperature, stimulation by light of an appropriate wavelength, concentration or availability of enzymes, concentration or availability of water, or other physiological conditions or compounds.

[0240] In another embodiment, polymeric materials can be used (see Medical Applications of Controlled Release, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974); Controlled Drug Bioavailability, Drug Product Design and Performance, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, 1983, J. Macromol. Sci. Rev. Macromol. Chem. 23:61; see also Levy et al., 1985, Science 228:190; During et al., 1989, Ann. Neurol. 25:351; Howard et al., 1989, J. Neurosurg. 71:105).

[0241] In another embodiment, a controlled release system can be placed near the target area to be treated, thereby requiring only a fraction of the systemic dose (see, e.g., Goodson, in Medical Applications of Controlled Release, supra, Vol. 2, pp. 115-138 (1984)). Other controlled release systems discussed in the review Langer, 1990, Science 249: 1527-1533) can be used.

[0242] Administration of any chimeric protein described herein (and / or additional agent) can be independently one to four times per day, or one to four times per month, or one to six times per year, or once every two, three, four, or five years. Administration can continue for a day or for a duration of one month, two months, three months, six months, one year, two years, three years, and can even continue for the lifetime of the subject.

[0243] The dosing regimen using any chimeric protein (and / or additional agent) described herein can be selected based on a variety of factors, including the type, race, age, weight, sex, and medical condition of the subject; the severity of the condition to be treated; the route of administration; the renal or liver function of the subject; the pharmacogenomic composition of the individual; and the specific compound of the invention employed. Any chimeric protein (and / or additional agent) described herein can be administered in a single daily dose, or the total daily dose can be administered in divided doses twice, three times, or four times daily. In addition, any chimeric protein (and / or additional agent) described herein can be administered continuously rather than intermittently throughout the dosage regimen.

[0244] Cells and nucleic acids

[0245] In an embodiment, the invention provides an expression vector comprising a nucleic acid encoding a chimeric protein as described herein. In an embodiment, the expression vector comprises DNA or RNA. In an embodiment, the expression vector is a mammalian expression vector.

[0246] Both prokaryotic and eukaryotic vectors can be used to express chimeric proteins. Prokaryotic vectors include constructs based on E. coli sequences (see, e.g., Makrides, Microbiol Rev 1996, 60:512-538). Non-limiting examples of regulatory regions that can be used for expression in E. coli include lac, trp, lpp, phoA, recA, tac, T3, T7, and λP. L. Non-limiting examples of prokaryotic expression vectors may include the λgt vector series such as λgt11 (Huynh et al., in "DNA Cloning Techniques, Vol. I: A Practical Approach," 1984, (D. Glover ed.), pp. 49-78, IRL Press, Oxford), and the pET vector series (Studier et al., Methods Enzymol 1990, 185: 60-89). However, the prokaryotic host-vector system cannot perform a large amount of post-translational processing on mammalian cells. Therefore, the eukaryotic host-vector system may be particularly useful. A variety of regulatory regions can be used to express chimeric proteins in mammalian host cells. For example, the SV40 early and late promoters, the cytomegalovirus (CMV) immediate early promoter, and the Rous sarcoma virus long terminal repeat (RSV-LTR) promoter can be used. Inducible promoters that can be used in mammalian cells include, but are not limited to, promoters associated with the metallothionein II gene, the mouse mammary tumor virus glucocorticoid responsive long terminal repeat (MMTV-LTR), the beta-interferon gene, and the hsp70 gene (see, Williams et al., Cancer Res 1989, 49: 2735-42; and Taylor et al., Mol Cell Biol 1990, 10: 165-75). Heat shock promoters or stress promoters may also be useful in driving the expression of chimeric proteins in recombinant host cells.

[0247] In an embodiment, the expression vector of the invention comprises a nucleic acid encoding a chimeric protein (and / or an additional agent), or its complement, operably linked to an expression control region, or its complement, that is functional in a mammalian cell. The expression control region is capable of driving the expression of an operably linked blocking agent and / or stimulating agent encoding nucleic acid, such that the blocking agent and / or stimulating agent is produced in a human cell transformed with the expression vector.

[0248] The expression control region is a regulatory polynucleotide (sometimes referred to herein as an element) that affects the expression of an operably linked nucleic acid, such as a promoter and an enhancer. The expression control region of the expression vector of the present invention enables the expression of an operably linked coding nucleic acid in a human cell. In one embodiment, the cell is a tumor cell. In another embodiment, the cell is a non-tumor cell. In an embodiment, the expression control region makes the expression of the operably linked nucleic acid adjustable. A signal (sometimes referred to as a stimulus) can increase or decrease the expression of a nucleic acid operably linked to such an expression control region. Such expression control regions that increase expression in response to a signal are generally referred to as inducibility. Such expression control regions that reduce expression in response to a signal are generally referred to as repressibility. Typically, the amount of increase or decrease imparted by such elements is proportional to the amount of signal present; the greater the amount of signal, the greater the increase or decrease in expression.

[0249] In embodiments, the present invention contemplates the use of an inducible promoter that can transiently achieve high levels of expression in response to a prompt. For example, when approaching a tumor cell, by exposing the transformed cell to an appropriate prompt, inducing cells transformed by an expression vector comprising a chimeric protein (and / or another agent) of such an expression control sequence to transiently produce a high level of agent. Exemplary inducible expression control regions include inducible expression control regions comprising an inducible promoter stimulated by a prompt (such as a small molecule compound). Specific examples can be found in, for example, U.S. Patent Nos. 5,989,910, 5,935,934, 6,015,709 and 6,004,941, each of which is incorporated herein by reference in its entirety.

[0250] Expression control regions and locus control regions include full-length promoter sequences (such as native promoters and enhancer elements), as well as subsequences or polynucleotide variants that retain all or part of the full-length or non-variant functions. As used herein, the term "functional" and its grammatical variants, when used in reference to a nucleic acid sequence, subsequence or fragment, means that the sequence has one or more functions of a native nucleic acid sequence (e.g., a non-variant or unmodified sequence).

[0251] As used herein, "operably linked" refers to the physical juxtaposition relationship of the components allowing them to function in a predetermined manner. In instances where an expression control element is operably linked to a nucleic acid, the relationship allows the control element to regulate the expression of the nucleic acid. Typically, the expression control region that regulates transcription is placed near the 5' end of the transcribed nucleic acid (i.e., "upstream"). The expression control region can also be located at the 3' end of the transcribed sequence (i.e., "downstream") or within the transcript (e.g., in an intron). The expression control element can be located at a distance from the transcribed sequence (e.g., 100 to 500, 500 to 1000, 2000 to 5000 or more nucleotides from the nucleic acid). A specific example of an expression control element is a promoter, which is typically located at the 5' of the transcribed sequence. Another example of an expression control element is an enhancer, which can be located at the 5' or 3' of the transcribed sequence, or inside the transcribed sequence.

[0252] Expression systems functional in human cells are well known in the art and include viral systems. Generally speaking, a promoter functional in human cells is any DNA sequence that can bind to mammalian RNA polymerase and initiate transcription of downstream (3') coding sequences into mRNA. The promoter will have a transcription initiation region, which is usually placed near the 5' end of the coding sequence, and the TATA box is usually located 25-30 base pairs upstream of the transcription start site. It is believed that the TATA box guides RNA polymerase II to start RNA synthesis at the correct site. The promoter also usually contains an upstream promoter element (enhancer element), which is usually located within 100 to 200 base pairs upstream of the TATA box. The upstream promoter element determines the transcription initiation rate and can work in any orientation. Promoters from mammalian viral genes are particularly suitable for use as promoters because viral genes are usually highly expressed and have a wide host range. Examples include SV40 early promoter, mouse mammalian tumor virus LTR promoter, adenovirus major late promoter, herpes simplex virus promoter and CMV promoter.

[0253] Typically, the transcription termination and polyadenylation sequences recognized by mammalian cells are regulatory regions located 3' of the transcription termination codon, and therefore flank the coding sequence together with the promoter element. The 3' end of the mature mRNA is formed by site-specific post-translational cleavage and polyadenylation. Examples of transcription terminators and polyadenylation signals include those derived from SV40. Introns may also be included in the expression construct.

[0254] There are a variety of techniques that can be used to introduce nucleic acids into living cells. Techniques suitable for transferring nucleic acids into mammalian cells in vitro include the use of liposomes, electroporation, microinjection, cell fusion, polymer-based systems, DEAE-dextran, viral transduction, calcium phosphate precipitation, and the like. For in vivo gene transfer, a variety of techniques and reagents can also be used, including liposomes; delivery vehicles based on natural polymers, such as chitosan and gelatin; viral vectors are also suitable for in vivo transduction. In some cases, it is desirable to provide targeting agents, such as antibodies or ligands that are specific for tumor cell surface membrane proteins. In the case of liposomes, proteins that bind to cell surface membrane proteins associated with endocytosis can be used to target and / or promote uptake, such as capsid proteins or fragments thereof that are proximal to specific cell types, antibodies to proteins that are internalized in the circulation, and proteins that target intracellular localization and enhance intracellular half-life. For example, the technique of receptor-mediated endocytosis is described in, for example, Wu et al., J. Biol. Chem. 262, 4429-4432 (1987); and Wagner et al., Proc. Natl. Acad. Sci. USA 87, 3410-3414 (1990).

[0255] Where appropriate, gene delivery agents may also be used, such as integration sequences. Many integration sequences are known in the art (see, for example, Nunes-Duby et al., Nucleic Acids Res. 26: 391-406, 1998; Sadwoski, J. Bacteriol., 165: 341-357, 1986; Bestor, Cell, 122 (3): 322-325, 2005; Plasterk et al., TIG 15: 326-332, 1999; Kootstra et al., Ann. Rev. Pharm. Toxicol., 43: 413-439, 2003). These include recombinases and transposases. Examples include Cre (Sternberg and Hamilton, J. Mol. Biol., 150:467-486, 1981), lambda (Nash, Nature, 247, 543-545, 1974), Flp (Broach, et al., Cell, 29:227-234, 1982), R (Matsuzaki, et al., J. Bacteriology, 172:610-618, 1990), cpC31 (see, e.g., Groth et al., J. Mol. Biol. 335:667-678, 2004), the mariner family of transposons Sleeping Beauty (Sleeping Beauty), and the like. Beauty) (Plasterk et al., supra) and components for integrating viruses (such as AAV, retroviruses and antivirals), which have components that provide viral integration, such as LTR sequences of retroviruses or lentiviruses and ITR sequences of AAV (Kootstra et al., Ann. Rev. Pharm. Toxicol., 43: 413-439, 2003). In addition, direct and targeted genetic integration strategies can be used to insert nucleic acid sequences encoding chimeric proteins, including CRISPR / CAS9, zinc fingers, TALEN and large-range nuclease gene editing technologies.

[0256] In one aspect, the invention provides an expression vector for expressing a chimeric protein (and / or an additional agent) that is a viral vector. Many viral vectors that can be used for gene therapy are known (see, e.g., Lundstrom, Trends Biotechnol., 21: 1 17, 122, 2003. Exemplary viral vectors include vectors selected from antiviral (LV), retrovirus (RV), adenovirus (AV), adeno-associated virus (AAV) and alpha virus, but other viral vectors may also be used. For in vivo use, viral vectors that are not integrated into the host genome, such as alpha virus and adenovirus, are suitable. Exemplary types of alpha viruses include Sindbis virus, Venezuelan equine encephalitis (VEE) virus and Semliki Forest virus (SFV). For in vitro use, viral vectors that integrate into the host genome are suitable, such as retrovirus, AAV and antiviral. In one embodiment, the invention provides a method for transducing human cells in vivo, comprising contacting a solid tumor with a viral vector of the invention in vivo.

[0257] In an embodiment, the present invention provides a host cell comprising an expression vector comprising the chimeric protein described herein.

[0258] The expression vector can be introduced into a host cell for producing the chimeric protein of the present invention. For example, the cell can be cultured in vitro or genetically engineered. Available mammalian host cells include, but are not limited to, cells derived from humans, monkeys, and rodents (see, for example, Kriegler in "Gene Transfer and Expression: A Laboratory Manual," 1990, New York, Freeman & Co.). These include monkey kidney cell lines transformed by SV40 (e.g., COS-7, ATCC CRL 1651); human embryonic kidney cell lines (e.g., 293, 293-EBNA, or subcloned 293 cells grown in suspension culture, Graham et al., J Gen Virol 1977, 36:59); baby hamster kidney cells (e.g., BHK, ATCC CCL 10); Chinese hamster ovary cells-DHFR (e.g., CHO, Urlaub and Chasin, Proc Natl Acad Sci USA 1980, 77:4216); DG44 CHO cells, CHO-K1 cells, mouse Sertoli cells (Mather, Biol Reprod 1980, 23:243-251); mouse fibroblasts (e.g., NIH-3T3), monkey kidney cells (e.g., CV1 ATCC CCL 70); African green monkey kidney cells (e.g., VERO-76, ATCC CRL-1587); human cervical cancer cells (e.g., HELA, ATCC CCL2); canine kidney cells (e.g., MDCK, ATCC CCL 34); Buffalo rat liver cells (e.g., BRL 3A, ATCC CRL1442); human lung cells (e.g., W138, ATCC CCL 75); human liver cells (e.g., Hep G2, HB 8065); and mouse breast tumor cells (e.g., MMT 060562, ATCC CCL51). Exemplary cancer cell types for expressing the chimeric proteins described herein include the mouse fibroblast cell line NIH3T3, the mouse Lewis lung cancer cell line LLC, the mouse mastocytoma cell line P815, the mouse lymphoma cell line EL4 and its ovalbumin transfectant E.G7, the mouse melanoma cell line B16F10, the mouse fibrosarcoma cell line MC57, and the human small cell lung cancer cell lines SCLC#2 and SCLC#7.

[0259] Host cells can be obtained from normal subjects or affected subjects (including healthy people, cancer patients, and patients with infectious diseases), private laboratory depositories, public culture collections such as the American Type Culture Collection, or commercial suppliers.

[0260] Cells that can be used to produce the chimeric protein of the present invention in vitro, ex vivo and / or in vivo include, but are not limited to, epithelial cells, endothelial cells, keratinocytes, fibroblasts, myocytes, hepatocytes; blood cells such as T lymphocytes, B lymphocytes, monocytes, macrophages, neutrophils, eosinophils, megakaryocytes, granulocytes; various stem cells or progenitor cells, in particular hematopoietic stem cells or progenitor cells (e.g., obtained from bone marrow, umbilical cord blood, peripheral blood, fetal liver, etc.). The choice of cell type depends on the type of tumor or infectious disease to be treated or prevented, and can be determined by a person skilled in the art.

[0261] The production and purification of Fc-containing macromolecules (such as monoclonal antibodies) have become standardized processes, with slight modifications between products. For example, many Fc-containing macromolecules are produced by human embryonic kidney (HEK) cells (or variants thereof) or Chinese hamster ovary (CHO) cells (or variants thereof), or in some cases produced by bacteria or synthetic methods. After production, the Fc-containing macromolecules secreted by HEK or CHO cells are purified by combining with protein A columns, and then various methods are used for 'polishing'. Generally speaking, the purified Fc-containing macromolecules are stored in liquid form for a period of time, frozen for a long time or lyophilized in some cases. In embodiments, compared with traditional Fc-containing macromolecules, the production of chimeric proteins considered herein can have unique characteristics. In some instances, specific chromatographic resins can be used or a chromatographic method that does not rely on protein A capture can be used to purify chimeric proteins. In embodiments, chimeric proteins can be purified in oligomeric states or multiple oligomeric states, and specific oligomeric states are enriched using ad hoc methods. Without being bound by theory, these methods can include processing with a specific buffer, which includes a specified salt concentration, pH and additive composition. In other examples, such methods may include treatments that favor one oligomeric state over another. The chimeric protein obtained herein may be additionally 'polished' using methods specified in the art. In embodiments, the chimeric protein is highly stable and can withstand extensive pH exposure (between pH 3-12), can withstand a large amount of freeze / thaw stress (greater than 3 freeze / thaw cycles) and can withstand extended incubation at high temperatures (longer than 2 weeks at 40 degrees Celsius). In embodiments, the chimeric protein is shown to remain intact under such stress conditions, with no signs of degradation, deamidation, etc.

[0262] Subjects and / or Animals

[0263] In embodiments, the subject and / or animal is a mammal, e.g., a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, rabbit, sheep, or non-human primate, such as a monkey, chimpanzee, or baboon. In embodiments, the subject and / or animal is a non-mammal, such as, for example, a zebrafish. In embodiments, the subject and / or animal may comprise fluorescently labeled cells (e.g., with GFP). In embodiments, the subject and / or animal is a transgenic animal comprising fluorescent cells.

[0264] In embodiments, the subject and / or animal is a human. In embodiments, the human is a young child. In embodiments, the human is an adult. In embodiments, the human is an elderly person. In embodiments, the human may be referred to as a patient.

[0265] In certain embodiments, the age of the human ranges from about 0 months to about 6 months, about 6 to about 12 months, about 6 to about 18 months, about 18 to about 36 months, about 1 to about 5 years, about 5 to about 10 years, about 10 to about 15 years, about 15 to about 20 years, about 20 to about 25 years, about 25 to about 30 years, about 30 to about 35 years, about 35 to about 40 years, about 40 to about 45 years, about 45 to about 50 years, about 50 to about 55 years, about 55 to about 60 years, about 60 to about 65 years, about 65 to about 70 years, about 70 to about 75 years, about 75 to about 80 years, about 80 to about 85 years, about 85 to about 90 years, about 90 to about 95 years, or about 95 to about 100 years.

[0266] In an embodiment, the subject is a non-human animal, and thus the invention relates to veterinary use. In a specific embodiment, the non-human animal is a household pet. In another specific embodiment, the non-human animal is a livestock animal.

[0267] Reagent test kit

[0268] The present invention provides kits that can simplify the administration of any agent described herein. Exemplary kits of the present invention include any composition described herein in unit dosage form. In one embodiment, the unit dosage form is a container, such as a prefilled syringe, which can be sterile, containing any agent described herein and a pharmaceutically acceptable carrier, diluent, excipient or vehicle. The kit may further include a label or printed instructions for the use of any agent described herein. The kit may also include an eyelid opener, a local anesthetic, and a cleaning agent for the application site. The kit may also further include one or more additional agents described herein. In one embodiment, the kit includes a container containing an effective amount of a composition of the present invention and an effective amount of another composition, such as those described herein.

[0269] Any aspect or embodiment described herein may be combined with any other aspect or embodiment as disclosed herein.

[0270] The present invention will be further described in the following examples, which do not limit the scope of the invention described in the claims.

[0271] Example

[0272] Example 1: Characterization of TIGIT-Fc-OX40L chimeric protein

[0273] In this example, chimeric proteins comprising TIGIT and OX40L domains were biochemically and functionally characterized.

[0274] Mouse TIGIT-Fc-OX40L chimeric protein and human TIGIT-Fc-OX40L chimeric protein were prepared; the schematic diagram is shown in Figure 3A and Figure 3B The top of the Figure is shown. mTIGIT-Fc-OX40L and hTIGIT-Fc-OX40L chimeric proteins were separated on SDS-PAGE under reducing conditions, after treatment with N+O deglycosylase, and / or after boiling. Western blots of mTIGIT-Fc-OX40L and hTIGIT-Fc-OX40L chimeric proteins indicated the presence of a dominant dimer band in the non-reducing lane ( Figure 3A and Figure 3B , lane 2 in each blot), which was reduced to a glycosylated monomeric band in the presence of the reducing agent β-mercaptoethanol ( Figure 3A and Figure 3B , lane 3 in each blot). Figure 3A and Figure 3B As shown in lane 3 in each blot, the chimeric protein was isolated as a monomer in the presence of both a reducing agent (β-mercaptoethanol) and an endoglycosidase (PNGase).

[0275] The binding affinity of the mTIGIT-Fc-OX40L chimeric protein and hTIGIT-Fc-OX40L chimeric protein was then determined. For each chimeric protein, an ELISA was performed under the following conditions: heavy + light chain capture and detection with Fc-HRP ( Figure 4A and Figure 4B , top left), captured by CD155 / PVR-His and detected by IgG ( Figure 4A and Figure 4B , top right), and OX40-His captured and detected with an antibody against mOX40L ( Figure 4A and Figure 4B , bottom left). The mTIGIT-Fc-OX40L chimeric protein was captured with OX40-Fc and detected with recombinant CD155 ( Figure 4A, bottom right, “Dual ELISA”), and hTIGIT-Fc-OX40L chimeric protein was captured with OX40-Fc and detected with recombinant CD155, CD112, or CD113 protein ( Figure 4A , bottom right, “Dual ELISA”). These data indicate that the mTIGIT-Fc-OX40L chimeric protein and hTIGIT-Fc-OX40L chimeric bind to each of their targets and can bind to both targets simultaneously.

[0276] Additional analysis was performed to determine whether the mTIGIT-Fc-OX40L chimeric protein could bind to its target on the surface of living cells. Cell lines were generated to overexpress human PVR (i.e., CHOK1 / PVR); these cells can be used to test the binding of TIGIT-containing constructs to cell membrane-associated PVR. See Figure 5A Generate cell lines to overexpress integrin-2 (i.e., CHOK1 / integrin-2); these cells can be used to test binding of TIGIT-containing constructs to cell membrane-associated integrin-2. Figure 5B Generate cell lines to overexpress integrin-3 (i.e., CHOK1 / integrin-3); these cells can be used to test binding of TIGIT-containing constructs to cell membrane-associated integrin-3. Figure 5C Another cell line overexpressing mOX40 (ie, CHOK1-mOX40) was prepared. Each cell line was based on Chinese Hamster Ovary K1 (CHOK1).

[0277] mTIGIT-Fc-OX40L chimeric protein or mPD-1-Fc-OX40L chimeric protein was incubated with parental and overexpressing cell lines for 2 hours. Cells were collected, washed and stained with antibodies for detection of chimeric protein binding by flow cytometry. Figure 6 As shown (bottom left and right), and as expected, the chimeric protein did not bind to the parental cell line at any concentration of the chimeric protein. However, mTIGIT-Fc-OX40L bound to the CHOK1 / PVR engineered cell line in a concentration-dependent manner; based on this data, the calculated EC 50 The value is 4.634nM. Figure 6 (Top left). In contrast, mPD-1-Fc-OX40L did not bind to any of the engineered cell lines. As with the CHOK1 / PVR engineered cell lines, the mTIGIT-Fc-OX40L chimeric protein also bound to the CHOK1-mOX40 engineered cell lines in a concentration-dependent manner; based on this data, the calculated EC 50 The value is 1.7nM. Figure 6 (Right). These data indicate that the different components of the chimeric protein are each able to bind to their respective receptors / ligands on living cells.

[0278] Microarray screening was next performed to further identify binding partners of hTIGIT-Fc-OX40L. Figure 7 is a table showing the results of identified binding partners of hTIGIT-Fc-OX40L from a microarray (containing approximately 6,000 human membrane proteins). Every expected binding partner of hTIGIT-Fc-OX40L was identified by screening. There was no evidence of non-specific binding to other human proteins, and binding to Galectin-1 was seen in the screen of all Fc-containing fusion proteins.

[0279] Example 2: Characterization of CD172a (SIRPα)-Fc-LIGHT chimeric protein

[0280] In this example, a chimeric protein comprising LIGHT and CD172a (SIRPα) domains was characterized biochemically and functionally.

[0281] Mouse CD172a (SIRPα)-Fc-LIGHT chimeric protein and human CD172a (SIRPα)-Fc-LIGHT chimeric protein were prepared; the schematic diagram is shown in Fig. 8A and Figure 8B The top of the figure is shown. mCD172a(SIRPα)-Fc-LIGHT and hCD172a(SIRPα)-Fc-LIGHT chimeric proteins were separated on SDS-PAGE under reducing conditions, after treatment with N+O deglycosylase, and / or after boiling. Western blot of mCD172a(SIRPα)-Fc-LIGHT and hCD172a(SIRPα)-Fc-LIGHT chimeric proteins indicated the presence of a dominant dimer band in the non-reducing lane ( Fig. 8A and Figure 8B , lane 2 in each blot), which was reduced to a glycosylated monomeric band in the presence of the reducing agent β-mercaptoethanol ( Fig. 8A and Figure 8B , lane 3 in each blot). Fig. 8A and Figure 8B As shown in lane 3 in each blot, the chimeric protein was isolated as a monomer in the presence of both a reducing agent (β-mercaptoethanol) and an endoglycosidase (PNGase).

[0282] The binding affinity of mCD172a (SIRPα)-Fc-LIGHT chimeric protein and hCD172a (SIRPα)-Fc-LIGHT chimeric protein was then determined. For each chimeric protein, ELISA was performed under the following conditions: heavy + light chain capture and Fc-HRP detection ( Fig. 9A and Fig. 9B, top left), CD47-His captured and detected with IgG ( Fig. 9A and Fig. 9B , top right), mouse LTBR-His captured and detected with an antibody against mouse LIGHT ( Fig. 9A , bottom left) or human LTBR-His captured and detected with an antibody against human LIGHT ( Fig. 9B , bottom left), and LTBR His+GST captured and detected with an antibody against SIRPα ( Fig. 9A and Fig. 9B , bottom right, “Dual ELISA”). These data indicate that the mCD172a(SIRPα)-Fc-LIGHT chimeric protein and hCD172a(SIRPα)-Fc-LIGHT chimeric bind to each of their targets and can bind to both targets simultaneously.

[0283] Additional analysis was performed to determine whether the mCD172a (SIRPα)-Fc-LIGHT chimeric protein could bind to its target on the surface of living cells. Fig. 10A , left) or CHO-K1 cells expressing mouse LTbR ( Fig. 10A , right side).

[0284] The mCD172a (SIRPα)-Fc-LIGHT chimeric protein was incubated with the parental and overexpressing cell lines for 2 hours. The cells were collected, washed and stained with antibodies for detection of chimeric protein binding by flow cytometry. Fig. 10A As shown (left), and as expected, the chimeric protein did not bind to the parental cell line at any concentration of the chimeric protein. However, mCD172a(SIRPα)-Fc-LIGHT bound to the mCD47 engineered cell line ( Fig. 10A , left) and mLTbR engineered cell lines ( Fig. 10A , right side); Based on this data, the EC of CD47 was calculated 50 The value was 18 nM, and the EC 50 The value was 24 nM. In addition, hCD172a (SIRPα)-Fc-LIGHT chimeric protein was incubated with mCD47 overexpressing cell lines. hCD172a (SIRPα)-Fc-LIGHT bound to the mCD47 engineered cell line ( Fig. 10B ); Based on this data, the calculated EC 50 The value was 57 nM. These data indicate that the different components of the chimeric protein are each able to bind to their respective receptor / ligand on living cells.

[0285] The human TIGIT-Fc-OX40L chimeric protein was then tested for its ability to not bind to erythrocytes and thereby cause hemolysis. Here, hCD172a(SIRPα)-Fc-LIGHT, hCD172a(SIRPα)-Fc-CD40 or CD47 specific antibodies (clone CC2C6 or CC900002) were incubated with cynomolgus monkey erythrocytes (RBC, Fig.11A , top and bottom on the left) or human RBCs ( Fig. 11B and Fig. 11C , all figures). When compared with treatment with Triton-X (as a positive control), neither hCD172a(SIRPα)-Fc-LIGHT nor hCD172a(SIRPα)-Fc-CD40 caused significant lysis of cynomolgus monkey RBCs ( Fig.11A , bottom left); showing an exemplary flat panel ( Fig.11A , right). Neither hCD172a(SIRPα)-Fc-LIGHT nor hCD172a(SIRPα)-Fc-CD40 significantly bound to human RBCs ( Fig. 11B , all Figures). When compared with treatment with Triton-X (as a positive control), hCD172a(SIRPα)-Fc-LIGHT or hCD172a(SIRPα)-Fc-CD40 caused almost undetectable levels of human RBC lysis ( Fig. 11C , all Figures); an exemplary flat plate ( Fig. 11C , right). These data indicate that hCD172a(SIRPα)-Fc-LIGHT and hCD172a(SIRPα)-Fc-CD40 do not cause hemolysis of human RBCs as an undesirable side effect.

[0286] Example 3: Characterization of PD-1-Fc-LIGHT chimeric protein

[0287] In this example, chimeric proteins comprising LIGHT and PD-1 domains were biochemically and functionally characterized.

[0288] Mouse PD-1-Fc-LIGHT chimeric protein and human PD-1-Fc-LIGHT chimeric protein were prepared; the schematic diagram is shown in Fig. 12A and Fig. 12B mPD-1-Fc-LIGHT and hPD-1-Fc-LIGHT chimeric proteins were separated on SDS-PAGE under reducing conditions, after treatment with N+O deglycosylase, and / or after boiling. Western blots of mPD-1-Fc-LIGHT and hPD-1-Fc-LIGHT chimeric proteins indicated the presence of a dominant dimer band in the non-reducing lane ( Fig. 12A and Fig. 12B, lane 2 in each blot), which was reduced to a glycosylated monomeric band in the presence of the reducing agent β-mercaptoethanol ( Fig. 12A and Fig. 12B , lane 3 in each blot). Fig. 12A and Fig. 12B As shown in lane 3 in each blot, the chimeric protein was isolated as a monomer in the presence of both a reducing agent (β-mercaptoethanol) and an endoglycosidase (PNGase).

[0289] The binding affinity of the mPD-1-Fc-LIGHT chimeric protein and hPD-1-Fc-LIGHT chimeric protein was then determined. For each chimeric protein, an ELISA was performed under the following conditions: heavy + light chain capture and detection with Fc-HRP ( Fig.13A and Fig. 13B , top left), mouse LTBR-His captured and detected with mouse LIGHT ( Fig.13A , top right) or human LTBR-His captured and detected with an antibody biotinylated to human LIGHT ( Fig. 13B , top right), and mPD-L1 captured and detected with antibodies against mLIGHT ( Fig.13A , bottom left, “Dual ELISA”) or hPDL1-Fc capture and detection with hLTBR-His / 6x His-HRP ( Fig.13A , bottom left, “Dual ELISA”). These data indicate that the mPD-1-Fc-LIGHT chimeric protein and the hPD-1-Fc-LIGHT chimeric bind to each of their targets and can bind to both targets simultaneously.

[0290] Additional analysis was performed to determine whether the murine PD-1-Fc-LIGHT chimeric protein ( Fig.14A ) or human PD-1-Fc-LIGHT chimeric protein ( Fig.14A ) can bind to its target on the surface of living cells. Fig.14A , left), CHO-K1 cells expressing mouse LTbR ( Fig.14A , right) and CHO-K1 cells expressing human mPD-L1 ( Fig. 14B , left). The mPD-1-Fc-LIGHT chimeric protein was incubated with the parental and overexpressing cell lines for 2 hours. The cells were collected, washed and stained with antibodies for detection of chimeric protein binding by flow cytometry. Fig.14A As shown (left and right), and as expected, the mPD-1-Fc-LIGHT chimeric protein did not bind to the parental cell line at any concentration of the chimeric protein. However, mPD-1-Fc-LIGHT bound to the mPD-L1 engineered cell line ( Fig.14A , left) and mLTbR engineered cell lines ( Fig.14A , right). In addition, hPD-1-Fc-LIGHT chimeric protein was incubated with hPD-L1 overexpressing cell lines. hPD-1-Fc-LIGHT binds to hPD-L1 engineered cell lines in a concentration-dependent manner ( Fig. 14B ); Based on this data, the calculated EC 50 The value was 48 nM. These data indicate that the different components of the chimeric protein are each able to bind to their respective receptors / ligands on living cells.

[0291] Example 4: Characterization of TIGIT-Fc-LIGHT chimeric protein

[0292] In this example, chimeric proteins comprising TIGIT and LIGHT domains were characterized biochemically and functionally.

[0293] Mouse TIGIT-Fc-LIGHT chimeric protein and human TIGIT-Fc-LIGHT chimeric protein were prepared; the schematic diagram is shown in Fig.15A and Fig. 15B mTIGIT-Fc-LIGHT and hTIGIT-Fc-LIGHT chimeric proteins were separated on SDS-PAGE under reducing conditions, after treatment with N+O deglycosylase, and / or after boiling. Western blots of mTIGIT-Fc-LIGHT and hTIGIT-Fc-LIGHT chimeric proteins indicated the presence of a dominant dimer band in the non-reducing lane ( Fig.15A and Fig. 15B , lane 2 in each blot), which was reduced to a glycosylated monomeric band in the presence of the reducing agent β-mercaptoethanol ( Fig.15A and Fig. 15B , lane 3 in each blot). Fig.15A and Fig. 15B As shown in lane 3 in each blot, the chimeric protein was isolated as a monomer in the presence of both a reducing agent (β-mercaptoethanol) and an endoglycosidase (PNGase).

[0294] The binding affinity of the mTIGIT-1-Fc-LIGHT chimeric protein and hTIGIT-1-Fc-LIGHT chimeric protein was then determined. For each chimeric protein, an ELISA was performed under the following conditions: heavy + light chain capture and detection with Fc-HRP ( Fig.16A and Fig. 16B , top left), CD155 / PVR captured and detected with Fc-HRP ( Fig.16A , top right) or CD155-His capture and detection ( Fig. 16B, top right), and mLTBR-His captured and detected with antibodies against mLIGHT ( Fig.16A , bottom left) or hCD155-Fc capture and detection with hLTBR-His / 6x His-HRP ( Fig. 16B , bottom left, “Dual ELISA”). These data indicate that the mTIGIT-1-Fc-LIGHT chimeric protein and hTIGIT-1-Fc-LIGHT chimera bind to each of their targets, and at least hTIGIT-1-Fc-LIGHT can bind to two targets simultaneously.

[0295] Additional analysis was performed to determine whether the murine TIGIT-1-Fc-LIGHT chimeric protein ( Fig.17 ) can bind to its target on the surface of living cells.

[0296] The mTIGIT-1-Fc-LIGHT chimeric protein or mPD-1-Fc-LIGHT chimeric protein was incubated with CHO-K1 cells expressing mouse PVR or expressing mouse integrin-2 ( Fig.17 , top left), CHO-K1 cells expressing mouse LTbR ( Fig.17 , right) or parental CHO-K1 cells ( Fig.17 , right and left bottom) were incubated together.

[0297] like Fig.17 As shown in (bottom left), and as expected, neither the mTIGIT-1-Fc-LIGHT chimeric protein nor the mPD-1-Fc-LIGHT chimeric protein bound to the parental cell line except at the highest concentration of the chimeric protein. However, mTIGIT-1-Fc-LIGHT bound to the mPVR engineered cell line in a concentration-dependent manner; based on this data, the calculated EC 50 The value is 214.9nM ( Fig.17 , top left). mTIGIT-1-Fc-LIGHT also bound to mLTbR-engineered cell lines in a concentration-dependent manner; based on this data, the calculated EC 50 The value is 11nM ( Fig.17 , right). These data indicate that the different components of the chimeric protein are each able to bind to their respective receptors / ligands on living cells.

[0298] Example 5: Further characterization of chimeric proteins

[0299] In this example, further experiments were performed using human TIGIT-Fc-LIGHT, human CD172a (SIRPα)-Fc-LIGHT, human PD-1-Fc-LIGHT, mouse PD-1-Fc-LIGHT, human TIGIT-Fc-OX40L, human TIGIT-Fc-LIGHT, and human CD172a (SIRPα)-Fc-LIGHT chimeric proteins.

[0300] Binding affinity measurements of human TIGIT-Fc-LIGHT, CD172a (SIRPα)-Fc-LIGHT or PD-1-Fc-LIGHT to human LTbR were collected by biomembrane interferometry using the Octet system (see, Fig.18A , all figures). The binding affinity measurements of human PD-1-Fc-LIGHT to recombinant human PD-L1 or PD-L2 were collected at a range of concentrations using the Octet system by biomembrane interferometry (see, Fig.18B ).

[0301] Binding affinity measurements of human TIGIT-Fc-OX40L and TIGIT-Fc-LIGHT to recombinant human CD155 / PVR (compared to a one-sided TIGIT-Fc fusion protein control) were collected by biomembrane interferometry using the Octet system (see, Fig.19A Binding affinity measurements of human CD172a(SIRPα)-Fc-LIGHT to recombinant human CD47 (compared to either a CD172a(SIRPα)-Fc control on one side or one of two CD47-specific antibody controls) were collected by biofilm interferometry using the Octet system (see, Fig.19B Binding affinity measurements of human PD-1-Fc-LIGHT to recombinant human PD-L1 (compared to a single-sided PD-1-Fc control or an anti-PD-L1 control: atezolizumab) were collected using the Octet system by biofilm interferometry (see, Fig.19C Binding affinity measurements of human CD172a (SIRPα)-Fc-LIGHT, TIGIT-Fc-LIGHT, or PD-1-Fc-LIGHT to recombinant human LTbR (compared to a single-sided LIGHT-Fc fusion protein control or anti-LTbR antibody) were collected using the Octet system by biomembrane interferometry (see, Fig.19D ).

[0302] The functional capacity of chimeric proteins containing the LIGHT domain or chimeric proteins containing the TIGIT domain was determined in a superantigen cytokine release assay. Here, increasing concentrations of Staphylococcal enterotoxin B (SEB) were used to activate human peripheral blood leukocytes in the presence of various test agents. Secretion of IL-2 ( Fig. 20A ) or TNFα( Fig. 20B ) as a functional readout of the ability of the test agent to block inhibitory signaling events or co-stimulatory immune activation signals.

[0303] Fig. 20A and Fig. 20B Shown is a superantigen cytokine release assay demonstrating the effects of various antibodies murine TIGIT-Fc-OX40L, murine CD172a (SIRPα)-Fc-LIGHT, murine TIGIT-Fc-LIGHT, or murine PD-1-Fc-LIGHT chimeric proteins on murine peripheral blood leukocytes activated by SEB. Fig. 20C A compilation of data at various superantigen (SEB) concentrations is shown. Fig. 20A and Fig. 20C As shown, when 50 and 200 ng / ml SEB was applied, each of the three concentrations (10 nM, 100 nM and 250 nM) provided significantly greater IL2 secretion than all antibody controls for mCD172a (SIRPα)-Fc-LIGHT and mPD-1-Fc-LIGHT. Fig. 20B As shown, when 50 and 200 ng / ml SEB were applied, mPD-1-Fc-LIGHT provided significantly greater TNFα secretion than all antibody controls at a concentration of 100 nm or 250 nm; when 200 ng / ml SEB was applied, all three concentrations of mCD172a(SIRPα)-Fc-LIGHT provided significantly greater TNFα secretion than all antibody controls.

[0304] also, FIG. 21A to FIG. 21C Superantigen cytokine release assays are shown, demonstrating that various antibodies human TIGIT-Fc-LIGHT ( Fig.21A )、human TIGIT-Fc-OX40L( Fig. 21B )、human PD-1-Fc-LIGHT and human CD172a(SIRPα)-Fc-LIGHT( Fig. 21C ) Effects of the chimeric protein on human peripheral blood leukocytes activated by SEB.

[0305] Thus, the above data demonstrate that the LIGHT domain-containing chimeric proteins and the TIGIT domain-containing chimeric proteins as described herein are capable of binding to each of their three binding partners; they functionally activate primary human leukocytes in vitro.

[0306] Example 6: Improved tumor killing and increased survival from treatment with chimeric proteins

[0307] The in vivo antitumor activity of murine TIGIT-Fc-OX40L, murine CD172a (SIRPα)-Fc-LIGHT, murine TIGIT-Fc-LIGHT, and murine PD-1-Fc-LIGHT chimeric proteins was analyzed using the CT26 mouse colorectal tumor model. In one set of experiments, Balb / c mice were inoculated with CT26 tumors. When tumors reached 4 to 5 mm in diameter, mice were treated with mTIGIT-Fc-OX40L, mCD172a (SIRPα)-Fc-LIGHT, mTIGIT-Fc-LIGHT, and mPD-1-Fc-LIGHT chimeric proteins or anti-TIGIT, anti-CD47, anti-OX40, or anti-PD-1 antibodies or a combination of anti-TIGIT and anti-OX40 antibodies.

[0308] Tumor growth was assessed for each treatment group, as Fig.22A As shown (left and right). Specifically, untreated mice rapidly developed tumors, and treatment with one or more antibodies appeared to slightly delay the development of tumors. In contrast, treatment of mice with mTIGIT-Fc-OX40L, mCD172a (SIRPα)-Fc-LIGHT, mTIGIT-Fc-LIGHT or mPD-1-Fc-LIGHT chimeric proteins significantly inhibited tumor growth and / or delayed tumor development.

[0309] The overall survival percentage of mice within 40 days after tumor inoculation was also assessed. All untreated mice died within 20 days after tumor inoculation, and none of the mice treated with one or more antibodies had a 40-day survival percentage greater than 25%; see Fig. 22B , left panel. Remarkably, all mice treated with mTIGIT-Fc-OX40L, mCD172a(SIRPα)-Fc-LIGHT, mTIGIT-Fc-LIGHT, or mPD-1-Fc-LIGHT chimeric proteins survived for more than 40 days after tumor inoculation; see Fig. 22B , right picture.

[0310] These data indicate that in vivo treatment with TIGIT-Fc-OX40L, CD172a (SIRPα)-Fc-LIGHT, TIGIT-Fc-LIGHT, or PD-1-Fc-LIGHT chimeric proteins inhibits tumor growth and improves survival.

[0311] Example 7: Characterization of the contribution of the Fc domain in the linker to the functionality of the chimeric protein

[0312] In this example, the contribution of the Fc domain in the linker to the functionality of the chimeric protein of the present invention was determined. Here, PD-1-Fc-OX40L was used as a model for an Fc-containing chimeric protein. Therefore, the data presented below are related to the chimeric protein of the present invention.

[0313] In its native state, PD-1 exists as a monomer, while OX40L tends to dimerize due to electrostatic interactions between the OX40L domains; the Fc domains associate with each other via disulfide bonds (e.g., through one or more of their cysteine ​​residues). In summary, several intermolecular interactions may contribute to the quaternary structure of PD-1-Fc-OX40L. There are at least four potential configurations of PD-1-Fc-OX40L, in which the chimeric protein exists as a monomer, dimer, trimer, or hexamer. See Fig.23 .

[0314] The presence of monomeric and dimeric configurations of the chimeric protein was tested by exposing the chimeric protein to reducing and non-reducing conditions and then separating the proteins on SDS-PAGE. Under non-reducing conditions (reduced: "-"), the chimeric protein migrated at about 200 kDa in SDS-PAGE. Here, the Western blots were probed with antibodies against PD-1, Fc, or OX40L, respectively, as shown in Figure 2. Fig.24 Left, middle and right blots shown in . Since the predicted monomer molecular weight of the chimeric protein is 57.6 kDa, the 200 kDa material is expected to be at least a dimer. However, under reducing conditions (reduced: "+"), which reduces disulfide bonds (e.g., located between Fc domains), the chimeric protein migrates to about 100 kDa in SDS-PAGE. Since the 100 kDa material is heavier than expected, it is predicted that the additional mass is due to glycosylation. Finally, the chimeric protein was treated with peptide-N-glycosidase F (PNGaseF "+") and separated on SDS-PAGE under reducing conditions. Under these conditions, the chimeric protein migrated to about 57.6 kDa. These data indicate that the chimeric protein is glycosylated and exists naturally at least as a dimer; wherein dimerization may be due to disulfide bonds between Fc domains, for example through one or more cysteine ​​residues thereof.

[0315] The SDS-PAGE gel method cannot accurately predict the molecular weight of highly charged and / or large molecular weight proteins. Therefore, size exclusion chromatography (SEC) was next used to characterize the chimeric protein. Unlike SDS-PAGE, where the negatively charged SDS reduces charge-based interactions between peptides, SEC does not use detergents or reducing agents. When the PD-1-Fc-OX40L chimeric protein was separated on SEC, there was no peak at approximately 200 kDa. This suggests that the chimeric protein does not naturally exist as a dimer. Instead, peaks with a size greater than 670 kDa were detected. See Fig.25 This and previous data suggest that the PD-1-Fc-OX40L chimeric protein exists in its native state as a hexamer.

[0316] As shown above, when separated on SDS-PAGE under non-reducing conditions or under reducing conditions, SDS in the sample and / or running buffer converts the hexameric PD-1-Fc-OX40L chimeric protein into predominantly dimers or monomers in the absence and presence of a reducing agent, respectively. Fig.26 (Gel on the left). When separated on native PAGE lacking SDS and in the absence of a reducing agent, the chimeric protein exists as a hexamer. However, when separated on native PAGE and in the presence of a reducing agent (which reduces disulfide bonds), the chimeric protein migrates heavier than expected; Fig.26 As shown (right gel, lane 2), the chimeric protein is essentially unable to migrate out of the well. This data suggests that the chimeric protein oligomerizes into higher order proteins. Therefore, in chimeric proteins, disulfide bonds appear to be important for controlling higher order oligomerization.

[0317] To further confirm this, a chimeric protein lacking an Fc domain, such as "PD-1-No Fc-OX40L", was constructed. Such a chimeric protein would not have the disulfide bonds that appear between the Fc domains in the aforementioned chimeric proteins. Fig. 27 As shown, when chimeric proteins lacking the Fc domain were separated on native PAGE, essentially none of the proteins migrated out of their loading wells; again indicating that the "no Fc" chimeric proteins had formed a concatemer-like complex containing many proteins. Therefore, omitting the Fc domain in the chimeric protein resulted in the formation of protein aggregates. These data indicate, for example, that disulfide bonds between the Fc domains on different chimeric proteins stabilize the chimeric proteins and ensure that they each exist as a hexamer rather than as a higher order protein / concatemer. In other words, the Fc domain surprisingly places order on the chimeric protein complex. Lanes #1 to #4 include 2.5 μg of PD-1-No Fc-OX40L, 5 μg of PD-1-No Fc-OX40L, 2.5 μg of PD-1-No Fc-OX40L, and 5 μg of PD-1-No Fc-OX40L, respectively.

[0318] Fig.28Shown in is a model summarizing the above data and illustrating how hexamers and concatemers are formed by the chimeric proteins of the invention. The exemplary chimeric protein (PD-1-Fc-OX40L) naturally forms hexamers (due to electrostatic interactions between the OX40L domains and dimerization of the Fc domains). However, in the absence of control over disulfide bonds between the Fc domains, under reducing conditions of the PD-1-Fc-OX40L protein and due to the absence of the Fc domain in PD-1-No Fc-OX40L, these latter chimeric proteins form concatemers.

[0319] In addition, a chimeric protein was constructed in which the Fc domain (as described herein) was replaced with Ficolin (which lacks the cysteine ​​residues necessary for disulfide bonds between the chimeric proteins). Like the Fc-free chimeric protein and the Fc-containing chimeric protein, and separated on native PAGE and in the presence of a reducing agent (both of which form aggregates that do not migrate into the gel), the Ficolin-containing chimeric protein also appears to form a higher order lattice that does not migrate into the gel. These data reinforce the conclusion that disulfide bonds are important for the correct folding and function of the chimeric proteins of the present invention.

[0320] Finally, chimeric proteins were prepared using a coiled Fc domain (CCDFc). Very little purified protein was delivered under functional evaluation.

[0321] Therefore, the inclusion of an Fc domain in the linker of the chimeric protein, which is capable of forming disulfide bonds between the chimeric proteins, helps to avoid the formation of insoluble and potentially non-functional protein concatemers and / or aggregates.

[0322] Example 8: Characterization of different linker sequences of chimeric proteins

[0323] Different unique linker sequences (17 linkers) with different characteristics (length, solubility, charge and flexibility) were identified. Each of these 17 linker sequences was then incorporated into the "Linker 2" position to synthesize constructs, wherein the configuration of the chimeric protein is:

[0324] ECD 1 – Linker 1 – Fc – Linker 2 – ECD 2

[0325] The production levels of these 17 constructs were tested in CHO cells. The following table provides different ligation linker sequences, the characteristics of these ligation linkers, the production levels (by A280) and the binding values ​​(EC values) based on FACS analysis for PD-L1 or OX40. 50 Some variation in production levels and activities between certain ligation linker sequences was determined.

[0326] Table 2: Summary of optional ligation linker sequences

[0327]

[0328]

[0329] FIG. 29A to FIG. 29Q The characterization of PD-1-IgG4-OX40L chimeric proteins with different junction linker sequences (17 linkers) by Western blot analysis is shown in . Specifically, each individual domain of the fusion construct was probed with anti-PD-1, anti-Fc or anti-OX40L antibodies. The results showed that each chimeric protein had similar performance, indicating that all candidate junction linker sequences were functional.

[0330] In addition, each purified protein with different linker sequences was also tested by binding to PD-L1 or OX40 in ELISA assays ( Fig.30 ) and cell-based flow cytometry assays ( FIG. 31A to FIG. 31P ) to characterize.

[0331] Example 9: Generation of additional TIGIT-containing chimeric proteins comprising the extracellular domains of other type II proteins

[0332] In this example, additional chimeric proteins of the invention are described. Such additional chimeric proteins are prepared in a manner similar to the preparation of TIGIT-Fc-OX40L, TIGIT-Fc-CD40L or TIGIT-Fc-LIGHT chimeric proteins, for example, as described in the above detailed description and in the priority document of this application: US62 / 464,002.

[0333] These additional chimeric proteins will have the following general formula: ECD 1 - Linker 1 - Fc domain - Linker 2 - ECD 2, wherein ECD 1 is the extracellular domain of TIGIT and ECD 2 is the extracellular domain of a type II protein other than CD40L, OX40L or LIGHT. Exemplary type II proteins include 4-1BBL, CD30L, FasL, GITRL, TL1A, and TRAIL. These chimeric proteins may lack one or both of the linkers. Exemplary linkers 1, Fc domains, and linkers 2 are described in Table 1 above; modular linkers for forming chimeric proteins and comprising specific linkers 1, Fc domains, and linkers 2 are described in Table 1 above. Fig.32 Shown in.

[0334] Alternatively, the additional chimeric protein is a fusion protein having the following general formula: N-terminus - (a) - (b) - (c) - C-terminus, wherein (a) is TIGIT, (b) is a linker comprising at least a portion of an Fc domain, and (c) is an extracellular domain of a type II protein other than CD40L, OX40L or LIGHT. Exemplary type II proteins include 4-1BBL, CD30L, FasL, GITRL, TL1A, and TRAIL. Exemplary linkers are described in Table 1 above; modular linkers for forming chimeric proteins and comprising specific linker 1, Fc domain, and linker 2 are described in Table 1. Fig.32 Shown in.

[0335] The amino acid sequences of 4-1BBL, CD30L, FasL, GITRL, TL1A and TRAIL include SEQ ID NOs: 12, 26, 30, 15, 18 and 40, respectively. The amino acid sequences of the extracellular domains of 4-1BBL, CD30L, FasL, GITRL, TL1A and TRAIL include SEQ ID NOs: 13, 27, 31, 16, 19 and 41, respectively. The amino acid sequence of TIGIT includes SEQ ID NO: 9, and the extracellular domain of TIGIT includes SEQ ID NO: 10. The chimeric protein may comprise a variant of the above-mentioned sequence, for example, having at least about 95% identity with the above-mentioned sequence.

[0336] Thus, the invention also includes the following additional chimeric proteins and methods of using the additional chimeric proteins (e.g., in treating cancer and / or treating inflammatory diseases): TIGIT-Fc-4-1BBL, TIGIT-Fc-CD30L, TIGIT-Fc-FasL, TIGIT-Fc-GITRL, TIGIT-Fc-TL1A and TIGIT-Fc-TRAIL.

[0337] The additional chimeric proteins will be characterized as described above for TIGIT-Fc-OX40L, TIGIT-Fc-CD40L or TIGIT-Fc-LIGHT in Examples 1 to 8, except that reagents specific for the additional chimeric proteins are not required for characterizing TIGIT-Fc-OX40L, TIGIT-Fc-CD40L or TIGIT-Fc-LIGHT (e.g., binding partners, recombinant target cells, and cancer cell / tumor types). Thus, using TIGIT-Fc-4-1BBL and TIGIT-Fc-CD40L as examples, anti-TIGIT, anti-Fc, and anti-4-1BBL antibodies other than the anti-TIGIT, anti-Fc, and anti-CD40L antibodies required for TIGIT-Fc-CD40L can be used to characterize TIGIT-Fc-4-1BBL similar to Example 1.

[0338] As with TIGIT-Fc-OX40L, TIGIT-Fc-CD40L or TIGIT-Fc-LIGHT chimeric proteins, additional chimeric proteins effectively treat cancer and / or treat inflammatory diseases by blocking TIGIT (which inhibits the transmission of immunosuppressive signals) and by activating a receptor / ligand of one of 4-1BBL, CD30L, FasL, GITRL, TL1A and TRAIL to enhance, increase and / or stimulate the transmission of immunosuppressive signals. In addition, additional chimeric proteins effectively treat cancer and / or inflammatory diseases, but without the toxicity and unwanted side effects, such as GI complications, caused by treatments including multiple antibodies (e.g., blocking antibodies and agonist antibodies to a receptor / ligand of one of 4-1BBL, CD30L, FasL, GITRL and TRAIL).

[0339] Example 10: Generation of additional LIGHT-containing chimeric proteins comprising the extracellular domains of other type I proteins

[0340] In this example, additional chimeric proteins of the invention are described. Such additional chimeric proteins are prepared in a manner similar to the preparation of CD172a (SIRPα)-Fc-LIGHT, TIGIT-Fc-LIGHT or PD-1-Fc-LIGHT chimeric proteins, for example, as described in the above specific embodiments and the priority document of this application: US62 / 464,002.

[0341] These additional chimeric proteins will have the following general formula: ECD 1 - linker 1 - Fc domain - linker 2 - ECD 2, wherein ECD 1 is the extracellular domain of a type I protein other than CD172a (SIRPα), TIGIT or PD-1, and ECD 2 is the extracellular domain of LIGHT. Exemplary type I proteins include TIM3 and BTLA. These chimeric proteins may lack one or both of the linkers. Exemplary linkers 1, Fc domains, and linkers 2 are described in Table 1 above; modular linkers for forming chimeric proteins and comprising specific linkers 1, Fc domains, and linkers 2 are described in Table 1 above; Fig.32 Shown in.

[0342] Alternatively, the additional chimeric protein is a fusion protein having the following general formula: N-terminus - (a) - (b) - (c) - C-terminus, wherein (a) is an extracellular domain of a type I protein other than CD172a (SIRPα), TIGIT or PD-1, (b) is a linker comprising at least a portion of an Fc domain, and (c) is an extracellular domain of LIGHT. Exemplary type I proteins include TIM3 and BTLA. Exemplary linkers are described in Table 1 above; modular linkers for forming chimeric proteins and comprising specific linker 1, Fc domain, and linker 2 are described in Table 1. Fig.32 Shown in.

[0343] The amino acid sequences of TIM3 and BTLA include SEQ ID NOs: 36 and 24, respectively. The amino acid sequences of the extracellular domains of TIM3 and BTLA include SEQ ID NOs: 37 and 25, respectively. The amino acid sequence of LIGHT includes SEQ ID NO: 1, and the extracellular domain of LIGHT includes SEQ ID NO: 2. The chimeric protein may include a variant of the above-mentioned sequence, for example, having at least about 95% identity with the above-mentioned sequence.

[0344] Therefore, the present invention also includes the following additional chimeric proteins and methods of using additional chimeric proteins (e.g., in treating cancer and / or treating inflammatory diseases): IM3-Fc-LIGHT and BTLA-Fc-LIGHT. The additional chimeric proteins will be characterized for CD172a (SIRPα)-Fc-LIGHT, TIGIT-Fc-LIGHT or PD-1-Fc-LIGHT as described above in Examples 1 to 8, except that reagents specific to the additional chimeric proteins that are not required for characterizing TIM3-Fc-LIGHT and BTLA-Fc-LIGHT (e.g., binding partners, recombinant target cells, and cancer cell / tumor types) are used; as an example, anti-TIGIT, anti-Fc, and anti-CD172a (SIRPα) antibodies other than the anti-TIGIT, anti-Fc, and anti-TIM3 antibodies required for CD172a (SIRPα)-Fc-LIGHT can be used to characterize TIM3-Fc-LIGHT similar to Example 2.

[0345] Like CD172a (SIRPα)-Fc-LIGHT, TIGIT-Fc-LIGHT or PD-1-Fc-LIGHT chimeric proteins, additional chimeric proteins effectively treat cancer and / or inflammatory diseases by blocking TIM3 and LIGHT (which inhibit the transmission of immunosuppressive signals) and enhancing, increasing and / or stimulating the transmission of immunosuppressive signals by LIGHT activation receptor / ligand. In addition, additional chimeric proteins effectively treat cancer and / or inflammatory diseases, but without toxicity and unwanted side effects caused by treatments including multiple antibodies (e.g., blocking antibodies and agonist antibodies to receptors / ligands of one of TIM3 and LIGHT), such as GI complications.

[0346] Equivalent

[0347] Although the invention has been described in conjunction with specific embodiments thereof, it will be appreciated that it is susceptible to further modifications and this application is intended to cover any changes, uses or adaptations of the invention generally in accordance with the principles of the invention, including changes that are not within the scope of the present disclosure but are known or customary implementations in the art to which the invention pertains and that are essential features described above and that fall within the scope of the appended claims.

[0348] Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation many equivalents to the specific embodiments specifically described herein. Such equivalents are intended to be encompassed within the scope of the following claims.

[0349] Incorporated by Reference

[0350] All patents and publications cited herein are incorporated by reference in their entirety.

[0351] The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention.

[0352] As used herein, all headings are for organizational purposes only and are not intended to limit the disclosure in any way. The contents of any individual section may apply equally to all sections.

[0353] Equivalent

[0354] Although the invention has been described in conjunction with specific embodiments thereof, it will be appreciated that it is susceptible to further modifications and this application is intended to cover any changes, uses or adaptations of the invention generally in accordance with the principles of the invention, including changes that are not within the scope of the present disclosure but are known or customary implementations in the art to which the invention pertains and that are essential features described above and that fall within the scope of the appended claims.

[0355] Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation many equivalents to the specific embodiments specifically described herein. Such equivalents are intended to be encompassed within the scope of the following claims.

Claims

1. A chimeric protein having the following general structure: N-terminus – (a) – (b) – (c) – C-terminus, in: (a) is a first domain comprising an extracellular domain of a type I transmembrane protein, the transmembrane protein being TIGIT, (b) is a linker comprising at least one cysteine ​​residue capable of forming a disulfide bond, and (c) is a second domain comprising an extracellular domain of a type II transmembrane protein selected from the group consisting of 4-1BBL, GITRL, TL1A and LIGHT, wherein: The linker connects the first domain and the second domain, and optionally comprises one or more connecting linkers, such connecting linkers are selected from SEQ ID NOs: 49-95.

2. The chimeric protein of claim 1, wherein the second domain is 4-1BBL.

3. The chimeric protein of claim 1, wherein the second domain is GITRL.

4. The chimeric protein of claim 1, wherein the second domain is TL1A.

5. The chimeric protein of claim 1, wherein the second domain is LIGHT.

6. A chimeric protein having the following general structure: N-terminus – (a) – (b) – (c) – C-terminus, in: (a) is a first domain comprising an extracellular domain of a type I transmembrane protein selected from the group consisting of PD-1, CD172a (SIRPα) and TIGIT, (b) is a linker comprising at least one cysteine ​​residue capable of forming a disulfide bond, and (c) is a second domain comprising an extracellular domain of a type II transmembrane protein, the transmembrane protein being LIGHT, wherein: The linker connects the first domain and the second domain, and optionally comprises one or more connecting linkers, such connecting linkers are selected from SEQ ID NOs: 49-95.

7. The chimeric protein of claim 6, wherein the first domain is PD-1.

8. The chimeric protein of claim 6, wherein the first domain is CD172a (SIRPα).

9. The chimeric protein of claim 6, wherein the first domain is TIGIT.

10. The chimeric protein of any one of claims 1 to 9, wherein the linker is a polypeptide selected from a flexible amino acid sequence, an IgG hinge region, or an antibody sequence.